0001558370-22-010732 | 6-K | XBRL Viewer

Print Document View Excel Document

Document and Entity Information	3 Months Ended
Document and Entity Information	Mar. 31, 2022
Document Information [Line Items]
Entity Registrant Name	Centogene N.V.
Entity Central Index Key	0001757097
Document Type	6-K
Document Period End Date	Mar. 31, 2022
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q1

Unaudited interim condensed consolidated statements of comprehensive loss - EUR (€)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Unaudited interim condensed consolidated statements of comprehensive loss
Revenue	€ 10,327,000	€ 9,981,000
Cost of sales	6,450,000	6,208,000
Gross profit	3,877,000	3,773,000
Research and development expenses	4,614,000	4,335,000
General administrative expenses	7,906,000	11,596,000
Selling expenses	2,394,000	1,949,000
Impairment of financial assets	154,000	95,000
Other operating income	733,000	366,000
Other operating expenses	1,000	34,000
Operating loss	(10,459,000)	(13,870,000)
Changes in fair value of warrants	238,000
Interest and similar income	1,000
Interest and similar expense	859,000	259,000
Financial costs, net	(620,000)	(259,000)
Loss before taxes from continuing operations	(11,079,000)	(14,129,000)
Income tax expenses	4,000
Loss for the period from continuing operations	(11,083,000)	(14,129,000)
Net income from discontinued operations, net of tax	4,601,000	9,240,000
Loss for the period	(6,482,000)	(4,889,000)
Other comprehensive income, all attributable to equity holders of the parent	94,000	121,000
Total comprehensive loss	(6,388,000)	(4,768,000)
Attributable to:
Equity holders of the parent	(6,415,000)	(4,803,000)
Noncontrolling interests from discontinued operations	27,000	35,000
Total comprehensive loss	€ (6,388,000)	€ (4,768,000)
Net loss per share - Continuing operations - Basic (in EUR)	€ (0.48)	€ (0.63)
Net loss per share - Continuing operations - Diluted (in EUR)	(0.48)	(0.63)
Net loss per share - Loss attributable to parent - Basic (in EUR)	(0.28)	(0.22)
Net loss per share - Loss attributable to parent - Diluted (in EUR)	€ (0.28)	€ (0.22)

Unaudited interim condensed consolidated statements of financial position - EUR (€) € in Thousands	Mar. 31, 2022	Dec. 31, 2021
Noncurrent assets
Intangible assets	€ 8,183	€ 9,194
Property, plant and equipment	7,674	9,464
Right-of-use assets	17,972	18,904
Other assets	2,972	2,972
Non-current assets	36,801	40,534
Current assets
Inventories	2,067	3,869
Trade receivables and contract assets	21,125	24,337
Other assets	5,443	5,453
Cash and cash equivalents	42,666	17,818
Current assets	71,301	51,477
Assets	108,102	92,011
Equity
Issued capital	3,250	2,708
Capital reserve	143,456	133,897
Retained earnings and other reserves	(114,120)	(107,705)
Noncontrolling interests	220	193
Equity	32,806	29,093
Noncurrent liabilities
Noncurrent loans	21,890
Lease liabilities	14,540	15,394
Deferred tax liabilities	59	79
Government grants	7,506	8,028
Warrants liability	2,603
Non-current liabilities	46,598	23,501
Current liabilities
Government grants	1,517	1,368
Current loans	3,574	3,815
Lease liabilities	2,953	3,330
Trade payables	5,897	11,252
Liabilities from income taxes	198	178
Other liabilities	14,559	19,474
Current liabilities	28,698	39,417
Equity and liabilities	€ 108,102	€ 92,011

Unaudited interim condensed consolidated statements of cash flows - EUR (€)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Operating activities
Loss before taxes from continuing operations	€ (11,079,000)	€ (14,129,000)
Income before taxes from discontinued operations	4,614,000	9,240,000
Loss before taxes	(6,465,000)	(4,889,000)
Adjustments to reconcile loss to cash flow from operating activities
Amortization and depreciation	3,808,000	3,286,000
Interest expense	859,000	259,000
Expected credit loss allowances on trade receivables and contract assets	146,000	95,000
Gain on disposal of property, plant and equipment	(527,000)
Sharebased payment (true up)/ expenses	(1,957,000)	2,042,000
Fair value adjustments of warrants	(238,000)
Other noncash items	(141,000)	(184,000)
Changes in operating assets and liabilities
Inventories	1,802,000	2,083,000
Trade receivables and contract assets	3,066,000	500,000
Other assets	10,000	(941,000)
Trade payables	(5,355,000)	(6,638,000)
Other liabilities	(4,908,000)	4,629,000
Thereof cash flow used in continuing operating activities	(12,735,000)	(8,720,000)
Thereof cash flow from discontinued operating activities	2,835,000	8,962,000
Net cash flow (used in)/ from operating activities	(9,900,000)	242,000
Investing activities
Cash paid for investments in intangible assets	(44,000)	(1,326,000)
Cash paid for investments in property, plant and equipment	(79,000)	(1,970,000)
Cash received for disposal of property, plant and equipment	575,000
Thereof cash flow from continuing investing activities	(123,000)	(1,526,000)
Thereof cash flow from discontinued investing activities	575,000	(1,770,000)
Cash flow from/ (used in) investing activities	452,000	(3,296,000)
Financing activities
Cash received from issuance of shares	12,058,000
Cash received from issuance of warrants	2,833,000
Cash received from loans	21,695,000	1,587,000
Cash repayments of loans	(200,000)	(185,000)
Cash repayments of lease liabilities	(1,231,000)	(1,222,000)
Interest paid	(859,000)	(61,000)
Thereof net cash flow from continuing financing activities	34,705,000	394,000
Thereof net cash flow used in discontinued financing activities	(409,000)	(275,000)
Net cash flow from financing activities	34,296,000	119,000
Changes in cash and cash equivalents	24,848,000	(2,935,000)
Cash and cash equivalents at the beginning of the period	17,818,000	48,156,000
Cash and cash equivalents at the end of the period	€ 42,666,000	€ 45,221,000

Unaudited interim condensed consolidated statements of changes in equity - EUR (€) € in Thousands	Total Owners' Capital Previously Reported	Total Owners' Capital Change	Total Owners' Capital	Issued capital Previously Reported	Issued capital	Capital reserve Previously Reported	Capital reserve	Currency translation reserve Previously Reported	Currency translation reserve	Retained earnings Previously Reported	Retained earnings Change	Retained earnings	Non-controlling interests. Previously Reported	Non-controlling interests.	Previously Reported	Change	Total
Balance at beginning of the period at Dec. 31, 2020			€ 65,682		€ 2,654		€ 125,916		€ (48)			€ (62,840)		€ 95			€ 65,777
Loss for the period			(4,924)									(4,924)		35			(4,889)
Other comprehensive loss			121						121								121
Total comprehensive loss			(4,803)						121			(4,924)		35			(4,768)
Share-based payments			2,042				2,042										2,042
Exercise of options					37		(37)
Balance at end of the period at Mar. 31, 2021			62,921		2,691		127,921		73			(67,764)		130			63,051
Balance at beginning of the period at Dec. 31, 2020			65,682		2,654		125,916		(48)			(62,840)		95			65,777
Loss for the period															€ (46,852)	€ 1,590	(45,262)
Total comprehensive loss															(46,309)	1,590	(44,719)
Balance at end of the period at Dec. 31, 2021	€ 27,310	€ 1,590	28,900	€ 2,708	2,708	€ 133,897	133,897	€ 495	495	€ (109,790)	€ 1,590	(108,200)	€ 193	193	€ 27,503	€ 1,590	29,093
Loss for the period			(6,509)									(6,509)		27			(6,482)
Other comprehensive loss			94						94								94
Total comprehensive loss			(6,415)		0		0		94			(6,509)		27			(6,388)
Share-based payments			(1,957)				(1,957)										(1,957)
Issuance of shares			12,058		537		11,521										12,058
Exercise of options					5		(5)
Balance at end of the period at Mar. 31, 2022			€ 32,586		€ 3,250		€ 143,456		€ 589			€ (114,709)		€ 220			€ 32,806

- Definition

The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners.

+ References + Details

- Definition

The amount of residual interest in the assets of the entity after deducting all its liabilities.

+ References + Details

- Definition

The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 7
-IssueDate 2021-01-01
-Paragraph 18
-Subparagraph b
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_18_b&doctype=Standard
-URIDate 2021-03-24

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 1
-IssueDate 2021-01-01
-Paragraph 24
-Subparagraph b
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2021-en-r&anchor=para_24_b&doctype=Standard
-URIDate 2021-03-24

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 1
-IssueDate 2021-01-01
-Paragraph 32
-Subparagraph a
-Clause ii
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2021-en-r&anchor=para_32_a_ii&doctype=Standard
-URIDate 2021-03-24

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 8
-IssueDate 2021-01-01
-Paragraph 28
-Subparagraph b
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_28_b&doctype=Standard
-URIDate 2021-03-24

Reference 5: http://www.xbrl.org/2003/role/exampleRef
-Note Effective on first application of IFRS 9
-Name IFRS
-Number 4
-IssueDate 2021-01-01
-Paragraph 39L
-Subparagraph e
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=4&code=ifrs-tx-2021-en-b&anchor=para_39L_e&doctype=Standard
-URIDate 2021-03-24

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 8
-IssueDate 2021-01-01
-Paragraph 23
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_23&doctype=Standard
-URIDate 2021-03-24

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Note Effective 2023-01-01
-Name IFRS
-Number 17
-IssueDate 2021-01-01
-Paragraph 113
-Subparagraph b
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2021-en-r&anchor=para_113_b&doctype=Standard
-URIDate 2021-03-24

Reference 8: http://www.xbrl.org/2003/role/exampleRef
-Name IFRS
-Number 12
-IssueDate 2021-01-01
-Paragraph B10
-Subparagraph b
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B10_b&doctype=Appendix&subtype=B
-URIDate 2021-03-24

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 1
-IssueDate 2021-01-01
-Paragraph 106
-Subparagraph d
-Clause i
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_106_d_i&doctype=Standard
-URIDate 2021-03-24

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 1
-IssueDate 2021-01-01
-Paragraph 81A
-Subparagraph a
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_81A_a&doctype=Standard
-URIDate 2021-03-24

+ Details

General company information

3 Months Ended

Mar. 31, 2022

General company information

General company information

1 General company information

Centogene N.V. (“the Company”) and its subsidiaries (“the Group”) focus on rare diseases and seek to transform real-world clinical and genetic or other data into actionable information for patients, physicians and pharmaceutical companies. The mission of the Company is to bring rationality to treatment decisions and to accelerate the development of new orphan drugs by using our knowledge of the global rare disease market, including epidemiological and clinical data and innovative biomarkers.

The Company is listed on the Nasdaq Global Market under stock code “CNTG”. Centogene N.V. is a public company with limited liability incorporated in the Netherlands, with registered office located at Am Strande 7 in 18055 Rostock, Germany and Dutch trade register number 72822872.

Basis of preparation

3 Months Ended

Mar. 31, 2022

Basis of preparation

Basis of preparation

2 Basis of preparation

The interim condensed consolidated financial statements for the three months ended March 31, 2022 and 2021 have been prepared in accordance with IAS 34 Interim Financial Reporting.

The interim condensed consolidated financial statements do not include all the information and disclosures required in the annual financial statements, and should be read in conjunction with the Group’s annual consolidated financial statements as of December 31, 2021 and 2020 and for the three years ended December 31, 2021. Unless otherwise specified, "the Company" refers to Centogene N.V. and Centogene GmbH throughout the remainder of these notes, while "the Group" refers to Centogene N.V., Centogene GmbH and its subsidiaries.

The accounting policies adopted in the preparation of the interim condensed consolidated financial statements are consistent with those followed in the preparation of the Group’s annual consolidated financial statements for the year ended December 31, 2021 except for the changes in presentation relating to discontinued operations (refer to Note 2.1– New significant accounting policies and accounting judgments and estimates and Note 7– Discontinued operations). The Group has not early adopted any standard, interpretation or amendment that has been issued but is not yet effective, and there are no new or amended standards or interpretations that are issued and became effective for the 2022 annual reporting period, that have a material impact on the Group.

These interim condensed consolidated financial statements are presented in euro, which is the Group's functional currency. Unless otherwise specified, all financial information presented in euro is rounded to the nearest thousand (EUR k) in line with customary commercial practice.

2.1New significant accounting policies and accounting judgments and estimates

Discontinued operations

A discontinued operation is a component of an entity that either has been disposed of, or that is classified as held for sale. It must either: represent a major separate line of business or geographical area of operations; be part of a single coordinated disposal plan; or be a subsidiary acquired exclusively with a view to resale. A component also qualifies for presentation as a discontinued operation when activities are ultimately ended (abandoned). Non-current assets and disposal groups are not classified as assets held for sale if their carrying amount is to be recovered through continuing use.

In 2021, the Group decided to end its COVID-19 business activities in Q1 2022. The Group assessed that ending the activities of this operating segment would qualify as a discontinued operation. Therefore, the profit or loss related to the COVID-19 business is presented in a separate line item of the profit and loss section of the statement of comprehensive loss for the three months ended March 31, 2022 and 2021. The segment reporting note and notes to the unaudited interim condensed consolidated financial statements for the three months ended March 31, 2022 and 2021 only represent continuing operations. For further details on the discontinued operations refer to Note 7 – Discontinued operations.

Warrants

Warrants are classified as equity to the extent that they confer the right to purchase a fixed number of shares for a fixed exercise price. In the event that the exercise price or the numbers of shares to be issued are not deemed to be fixed, the warrants are classified as a non-current derivative financial liability. Warrants entitle the holder to purchase one common share of the Company at an exercise price of USD 7.72 per share and can be settled for a fixed number of the Company's underlying common shares. Since the exercise price of the warrants is determined in US dollars which is different from the Company’s functional currency, warrants are classified as liabilities. This liability is initially recognized at its fair value on the date the contract is entered into and subsequently accounted for at fair value through profit and loss (FVTPL) at each reporting date. As the warrants are classified as financial liabilities at FVTPL, transaction costs in the amount of EUR 68k were expensed in the consolidated statements of comprehensive loss for the three months ended March 31, 2022. For more details, refer to Note 13 – Financial instruments at fair value.

2.2Revision of selected assets and liabilities in the consolidated statement of financial position and selected income and expenses in the consolidated statement of comprehensive loss

In accordance with IAS 8.42, the Group revised the amount presented for certain property, plant and equipment and lease liabilities balances on the consolidated statement of financial position and cost of sales and other operating income amounts in the statements of comprehensive loss as of and for the year ended December 31, 2021 These revised assets, liabilities, income and expenses are related to the COVID-19 segment which has been discontinued as of March 31, 2022.

In September 2021, management updated their long term COVID-19 outlook and took the decision to wind down the COVID-19 segment by Q1 2022. This resulted in an accelerated depreciation of COVID-19 segment related property, plant and equipment and right of use assets during Q4 2021.

In Q2 2022, management identified the accelerated depreciation was over-stated with an amount of EUR 1,317k and a terminated lease contract in Q4 2021 with a EUR 273k lease liability balance which was not derecognized from the statement of financial position as of December 31, 2021. The lease liability is in relation to the closure of the Hamburg laboratory of which the right of use asset was completely written off in Q3 2021.

To correct these unadjusted differences, property, plant and equipment has been revised by EUR 1,317k with a corresponding decrease in depreciation expense under cost of sales and lease liabilities have been revised by EUR 273k with a corresponding increase in other operating income.

The changes to the consolidated statement of financial position as of December 31, 2021 are as follows:


in EUR k	Dec 31, 2021 (as previously reported)	Adjustment	Dec 31, 2021 (revised)
Property, plant & equipment	8,147	1,317	9,464
Non-current Assets	39,217	1,317	40,534
Total assets	90,694	1,317	92,011

Retained earnings and other reserves	(109,295)	1,590	(107,705)
Equity	27,503	1,590	29,093

Lease liabilities	15,588	(194)	15,394
Non-current liabilities	23,695	(194)	23,501
Lease liabilities	3,409	(79)	3,330
Current liabilities	39,496	(79)	39,417
Total Liabilities	63,191	(273)	62,918

The changes to the consolidated statements of comprehensive income for the year ended December 31, 2021 are as follows:


	Dec 31, 2021 (as previously reported)	Adjustment	Dec 31, 2021 (revised)
Revenue	189,923	-	189,923
Cost of sales	161,765	(1,317)	160,448
Gross profit	28,158	1,317	29,475
Research and development expenses	19,297	-	19,297
General administrative expenses	46,739	-	46,739
Selling expenses	9,860	-	9,860
Impairment of financial assets	1,140	-	1,140
Other operating income	2,936	273	3,209
Other operating expenses	86	-	86
Operating loss	(46,028)	1,590	(44,438)
Loss for the year	(46,852)	1,590	(45,262)
Total comprehensive loss	(46,309)	1,590	(44,719)
Loss per share- Basic and diluted (in EUR)	(2.06)	0.08	(1.98)

The revisions above have no impact on the changes in cash, cash equivalents and net cash flows in operating, investing, and financing activities within the consolidated statements of cash flows for the year ended December 31, 2021.

Effect of COVID-19 Pandemic and other geopolitical events

3 Months Ended

Mar. 31, 2022

Effect of COVID-19 Pandemic and other geopolitical events

Effect of COVID-19 Pandemic and other geopolitical events

3 Effect of COVID-19 Pandemic and other geopolitical events

The COVID-19 pandemic has spread worldwide and continues to cause many governments to maintain measures to slow the spread of the outbreak through quarantines, travel restrictions, closures of borders and requiring maintenance of physical distance between individuals.

The COVID-19 pandemic resulted in a slowdown in our diagnostics and pharmaceutical businesses. As part of the Company’s initiative to assist local, national and international authorities as well as other partners in their efforts to facilitate the earliest possible diagnosis of COVID-19 and thereby contribute to allowing society to return to a “new” normal, the Company commenced testing for COVID-19 in March 2020.

During the three months ended March 31, 2022, we continued the COVID-19 testing activities that started in 2020. However, as at March 31, 2022, all COVID-19 operations at testing sites have ceased as all COVID-19 testing site contracts expired within the first quarter of 2022. The company is reporting the COVID-19 segment as a discontinued operation. See Note 2.1– New significant accounting policies and accounting judgments and estimates and Note 7 – Discontinued operations.

Although the Group is taking a number of measures aimed at minimizing disruptions to the business and operations, the full extent to which the global COVID-19 pandemic may continue to impact the business will depend on future developments, which are highly uncertain and cannot be predicted, such as the duration of the pandemic, the availability and effectiveness of vaccines against new variants, the probability of the occurrence of further outbreaks and the ultimate impact on the financial markets and the global economy could result in an unforeseen negative impact on the business and future results of operations.

In reaction to the recognition of the so-called Donetsk People’s Republic and the so-called Luhansk People’s Republic by the Russian Federation, the following Russian invasion of the Ukraine on February 24, 2022 and the since-then ongoing war in the Ukraine, a number of countries (including the United States, United Kingdom and the European Union) imposed sanctions and other measures. Sanctions and other measures imposed until July 2022 against, among others, certain individuals as well as private and state-owned entities in Russia and Belarus, include asset freezes, exports controls through tariffs, taxation or bans of goods and commodities and energy embargos,

including a ban by the United States of oil, gas and coal imports, financial sanctions and bans of foreign direct investments into Russia. Additional sanctions may be imposed.

Due to the war in Ukraine, there has been a significant increase in volatility on the securities and currency markets. It is expected that these events may affect the activities of Russian enterprises in various sectors of the economy and may have severe effects on macroeconomic developments in global and national markets due to spillovers and Russian counter measures, including on commodity markets and financial channels, contributing to supply chain disruptions and rising inflation. Although neither Centogene’s operations, supply chain, performance nor going concern basis has been significantly affected by the conflict, the impact of the conflict and its broader economic implications, such as higher costs of consumer goods, cannot be reliably quantified at this point in time.

Revenues from contracts with customers

3 Months Ended

Mar. 31, 2022

Revenues from contracts with customers

Revenues from contracts with customers

4 Revenues from contracts with customers


in EUR k	For the three months ended March 31, 2022
	Pharmaceutical	Diagnostics	Total
Rendering of services	3,047	7,092	10,139
Sales of goods	188	—	188
Total Revenues from contracts with external customers	3,235	7,092	10,327

Recognized over time	3,047	7,092	10,139
Recognized at a point in time	188	—	188
Total Revenues from contracts with external customers	3,235	7,092	10,327

Geographical information
Europe	18	1,421	1,439
—Germany*	—	78	78
—Netherlands**	—	7	7
Middle East	58	4,033	4,091
—Saudi Arabia#	—	2,421	2,421
North America	3,145	625	3,770
—United States#	3,145	604	3,749
Latin America	14	715	729
Asia Pacific	—	298	298
Total Revenues from contracts with external customers	3,235	7,092	10,327


in EUR k	For the three months ended March 31, 2021
	Pharmaceutical	Diagnostics	Total
Rendering of services	3,393	6,383	9,776
Sales of goods	205	—	205
Total Revenues from contracts with external customers	3,598	6,383	9,981

Recognized over time	3,393	6,383	9,776
Recognized at a point in time	205	—	205
Total Revenues from contracts with external customers	3,598	6,383	9,981

Geographical information
Europe	149	1,214	1,363
—Germany*	—	53	53
—Netherlands**	—	2	2
Middle East	29	4,135	4,164
—Saudi Arabia#	—	2,683	2,683
North America	3,405	464	3,869
—United States#	3,405	403	3,808
Latin America	15	410	425
Asia Pacific	—	160	160
Total Revenues from contracts with external customers	3,598	6,383	9,981

* country of the incorporation of Centogene GmbH

** country of the incorporation of Centogene N.V.

# countries contributing more than 10% of the Group’s total consolidated revenues for the three months ended March 31, 2022 and 2021, respectively.

The Group collaborated with the majority of our existing pharmaceutical partners on a worldwide basis in 2022 and 2021. In addition, in cases where pharmaceutical partners are developing a new rare disease treatment, it is generally anticipated that the final approved treatment will be made available globally. As a result, the Group allocates the revenues of the pharmaceutical segment by geographical region by reference to the location where each pharmaceutical partner mainly operates, which is based on the region from which most of their revenues are generated. The allocation of revenues in the diagnostics segment is based on the location of each customer.

Pharmaceutical segment

During the three months ended March 31, 2022, revenues from one pharmaceutical partner represented 19.0% of the Group's total revenues (the three months ended March 31, 2021: 30.5%).

Segment information

3 Months Ended

Mar. 31, 2022

Segment information

Segment information

5 Segment information


in EUR k	For the three months ended March 31, 2022
	Pharmaceutical	Diagnostics	Corporate	Total
Total Revenues from contracts with external customers	3,235	7,092	—	10,327

Adjusted EBITDA	1,099	812	(11,964)	(10,053)

Capital Expenditures
Additions to property, plant and equipment and right-of-use assets	—	—	79	79
Additions to intangible assets	29	—	15	44

Other segment information
Depreciation and amortization	127	441	1,795	2,363
Research and development expenses	—	—	4,614	4,614


in EUR k	For the three months ended March 31, 2021
	Pharmaceutical	Diagnostics	Corporate	Total
Total Revenues from contracts with external customers	3,598	6,383	—	9,981

Adjusted EBITDA	1,497	1,054	(12,020)	(9,469)

Capital Expenditures
Additions to property, plant and equipment and right-of-use assets	6	234	314	554
Additions to intangible assets	322	—	650	972

Other segment information
Depreciation and amortization	414	406	1,539	2,359
Research and development expenses	—	—	4,335	4,335

Adjusted EBITDA

Adjustments to income/ loss include non-cash charges in relation to depreciation, amortization (including impairments), and share-based payments as well as net financial costs and income taxes. Certain costs, and related income, are not allocated to the reporting segment results and represent the residual operating activities of the Group reported as ‘Corporate’. These include financing costs which is largely composed of costs related to the Oxford Loan Facility (as defined below), corporate overheads, which are responsible for centralized functions such as communications, information technology, facilities, legal, finance and accounting, insurance (D&O), human resources, business development and strategic initiatives, certain professional and consulting services, procurement, research and development and other supporting activities.

Decreases in corporate expenses for the three months ended March 31, 2022 are mainly due to decreased personnel costs, legal, administrative, IT support and data center costs.

Reconciliation of segment Adjusted EBITDA to Group loss before taxes from continuing operations


For the three months ended March 31	2022	2021
Reported segment Adjusted EBITDA	1,911	2,551
Corporate expenses	(11,964)	(12,020)
	(10,053)	(9,469)
Share-based payment (true-up)/ expenses (Note 12)	1,957	(2,042)
Depreciation and amortization	(2,363)	(2,359)
Operating loss from continuing operations	(10,459)	(13,870)
Financial costs, net	(620)	(259)
Loss before taxes from continuing operations for the three months ended March 31	(11,079)	(14,129)

Non-current asset locations

Non-current assets of the Group consist of right-of-use assets (under IFRS 16), property, plant and equipment, as well as intangible assets. All of such assets are located in Germany, which is the country of the business address of Centogene GmbH, except for property, plant and equipment of EUR 132k (December 31, 2021: EUR 147k) and right-of-use assets of EUR 69k (December 31, 2021: EUR 137k), which are located in the United States.

Other income and expenses

3 Months Ended

Mar. 31, 2022

Other income and expenses

Other income and expenses

6 Other income and expenses

6.1Other operating income


	For the three months ended March 31
in EUR k	2022	2021
Government grants	553	340
Others	180	26
Total other operating income	733	366

Government grants contain performance-based grants to subsidize research, development and innovation in the state of Mecklenburg-Western Pomerania from funds granted by the European Regional Development Fund. Furthermore, government grants contain the release of deferred income from investment related grants.

6.2Other operating expenses


	For the three months ended March 31
in EUR k	2022	2021
Currency losses	1	34
Total other operating expenses	1	34

Discontinued operations

3 Months Ended

Mar. 31, 2022

Discontinued operations

Discontinued operations

7 Discontinued operations

At the end of the third quarter of 2021, management updated its long term outlook for the COVID-19 testing business, which led to management’s decision to initiate a wind down process in which lease contracts at unprofitable COVID-19 testing sites would not be renewed. Similarly, COVID-19 related inventory levels were significantly ramped down to align with the needs of the remaining test sites and laboratories.

As at March 31, 2022, operations at all COVID-19 testing sites have ceased. The Company has no intentions of renewing any of the COVID-19 testing site leases and has abandoned the COVID-19 business line. Consequently, the Company is reporting its COVID-19 segment as a discontinued operation.

All COVID-19 related property, plant and equipment have been fully depreciated as at March 31, 2022. In addition, all COVID-19 related accounts receivable and accounts payable are included in the balance sheet as at March 31, 2022 whilst all COVID-19 related inventory have been written down to zero.

The Group has COVID-19 related advertising expenses, credit card fees and other selling expenses which were recognized under cost of sales in the statement of comprehensive loss since the COVID-19 business was added to the operations of the Group in the first quarter of 2020. During the 2021 year-end closing process, management identified this as a classification error and corrected it retrospectively. Accordingly, the Group reclassified EUR 1,192k from cost of sales to general administration expenses and selling expenses in the amount of EUR 999k and EUR 193k, respectively, for the three months ended March 31, 2021.

Discontinued operations are presented separately from continuing operations in the consolidated statements of comprehensive loss and consolidated statements of cash flows.


	For the three months ended March 31
	2022	2021
Results of discontinued operations
Revenue	19,463	54,979
Cost of sales	15,200	44,547
Gross profit	4,263	10,432
General administrative expenses	302	999
Selling expenses	7	193
Other operating income	706	-
Operating income	4,660	9,240
Financial costs, net	46	-
Income before taxes	4,614	9,240
Income tax expense	13	-
Income for the period	4,601	9,240
Total comprehensive income, attributable to equity holders of the parent	4,601	9,240
Net income per share - Basic and diluted (in EUR)	0.20	0.41

Cash flow from discontinued operations
Net cash flow from operating activities	2,835	8,962
Net cash flow from/ (used in) investing activities	575	(1,770)
Net cash flow used in financing activities	(409)	(275)

Trade receivables and other assets

3 Months Ended

Mar. 31, 2022

Trade receivables and other assets.

Trade receivables and other assets

8 Trade receivables and other assets


in EUR k	Mar 31, 2022	Dec 31, 2021
Non‑current
Other assets - Rental deposits	2,922	2,922
Other assets – Others	50	50
	2,972	2,972
Current
Trade receivables, net	18,209	21,065
Contract assets, net	2,916	3,272
Other assets	5,443	5,453
	26,568	29,790
Total non-current and current trade receivables and other assets	29,540	32,762

Other non-current assets

The non-current portion of other assets mainly include cash deposits of EUR 2,250k used to secure a bank guarantee of EUR 3,000k relating to the leases of Rostock headquarters building, cash deposits of EUR 193k, used to secure a bank guarantee of EUR 257k, relating to the leases of Berlin office and EUR 190k for the leases of certain plant and

machineries. It also includes the non-current part of the consideration receivable for the sale of the Laboratory Process Consulting GmbH for EUR 50k.

Trade receivables and contract assets

Trade receivables are non-interest bearing and are generally due in 30 to 90 days. In general, portfolio-based expected credit loss allowances are recognized on trade receivables and contract assets. The outstanding gross COVID-19 related accounts receivables balance as at March 31, 2022 is EUR 8,013k (December 31, 2021: EUR 8,263k).


in EUR k	Mar 31, 2022		Dec 31, 2021
Not past due	9,355		17,978
Past due 1-30 days	2,743		1,476
Past due 31-90 days	6,487		2,596
Past due more than 90 days	8,403		8,004
Total gross amount of trade receivables and contract assets	26,988		30,054

Expected credit loss rate
Not past due	1.5	%	0.9	%
Past due 1-30 days	6.9	%	7.7	%
Past due 31-90 days	4.8	%	11.7	%
Past due more than 90 days	62.1	%	64.1	%
Expected credit loss rate on total gross trade receivables and contract assets	21.7	%	19.0	%

Expected credit loss	5,863		5,717

The addition to the allowance for expected credit losses amounts to EUR 146k, which was included in the impairment of financial assets in the profit and loss account (the three months ended March 31, 2021: EUR 95k).

Other current assets

The current assets include VAT receivables of EUR 346k (December 31, 2021: EUR 253k), prepaid expenses of EUR 3,128k (December 31, 2021: EUR 3,346k), receivables related to exercised share-based payment grants of EUR 185k (December 31, 2021: EUR 116k), receivables related to COVID-19 bank or credit card transactions of EUR nil (December 31, 2021: EUR 612k), as well as receivables from grants of EUR 173k (December 31, 2021: EUR nil).

Cash and short-term deposits

3 Months Ended

Mar. 31, 2022

Cash and short-term deposits

Cash and short-term deposits

9 Cash and short-term deposits

As of March 31, 2022, the Group has pledged its short-term deposits with carrying amount of EUR 938k (December 31, 2021: EUR 938k) and EUR 2,500k (December 31, 2021: EUR 2,500k) respectively, to fulfil collateral requirements in respect of existing secured bank loan and overdraft facility up to EUR 2,500k. In addition, the Group has pledged its short-term deposits of EUR 1,000k (December 31, 2021: EUR 1,000k) related to two other overdraft facilities worth EUR 500k each.

The restriction applying to the collateral may be terminated at any time subject to the full amount of the relevant bank loans and the overdrafts being repaid.

Equity

3 Months Ended

Mar. 31, 2022

Equity.

Equity

10 Equity

Common Shares

As of March 31, 2022, 27,081,557 common shares of Centogene N.V. with a nominal value of EUR 0.12 were issued and fully paid up (December 31, 2021: 22,567,971). As of March 31, 2022, the authorized but unissued common share capital amounted to EUR 6,230k (December 31, 2021: EUR 6,772k).

On January 31, 2022, pursuant to a security purchase, each signed with certain investors, the Group received EUR 15.0 million in exchange for the issuance of an aggregate of 4,479,088 common shares at a price per share of USD 3.73 (EUR 3.35).

The holders of common shares are entitled to the Company's approved dividends and other distributions as may be declared from time to time by the Company, and are entitled to a vote per share on all matters to be voted at the Company's annual general meetings.

Capital reserve

On January 31, 2022, pursuant to the above mentioned securities purchase agreement and a warrant agreement, each signed with certain investors, the Group received EUR 15.0 million in exchange for the issuance of an aggregate of 4,479,088 common shares at a price per share of USD 3.73 (EUR 3.35) and warrants initially exercisable for the purchase of up to an aggregate of 1,343,727 additional common shares at an initial exercise price per common share of USD 7.72. The warrants are exercisable immediately as of the date of issuance and will expire on December 31, 2026. The fair value of warrants issued as of January 31, 2022 was USD 3.2 million (EUR 2.8 million). There is no impact on the diluted earnings per share (EPS) since the warrants do not represent potential voting rights due to the high exercise price in comparison to current market price. The amount recognized in capital reserve for the issuance of shares considering EUR 110k of transaction costs, was EUR 14.3 million. EUR 2.8 million for the issuance of warrants was also charged against capital reserve reducing the EUR 14.3 million from the issuance of shares to EUR 11.5 million.

As of March 31, 2022, capital reserve included a share premium of EUR 118,142k (December 31, 2021: EUR 106,665k), being amounts paid in by shareholders at the issuance of shares in excess of the par value of the shares issued, net of any transaction costs incurred for the share issuance.

In addition, it also included amounts recorded in respect of share-based payments. For additional information on share-based payments, see Note 12 – Share-based payments

Financial liabilities

3 Months Ended

Mar. 31, 2022

Financial liabilities

Financial liabilities

11 Financial liabilities

11.1Interest-bearing liabilities


in EUR k	Mar 31, 2022	Dec 31, 2021
		Revised
Non‑current liabilities
Non‑current portion of secured bank loans	21,890	—
Total non‑current loans	21,890	—
Lease liabilities*	14,540	15,394
Total non‑current liabilities	36,430	15,394

Current liabilities
Current portion of secured bank loans	301	505
Bank overdrafts	3,273	3,310
Total current loans	3,574	3,815
Current portion of lease liabilities*	2,953	3,330
Total current liabilities	6,527	7,145

Total non‑current and current liabilities	42,957	22,539

* Lease liabilities as of December 31,2021 have been revised. Refer to Note 2.2 – Revision of selected assets and liabilities in the consolidated statement of financial position and selected income and expenses in the consolidated statement of comprehensive loss.

On January 31, 2022 the Company, Centogene GmbH, CentoSafe B.V. and Centogene US, LLC (together, the “Borrowers”), entered into a debt financing agreement in the total amount of up to USD 45.0 million (EUR 40.2 million), (the “Loan Facility”). Under the terms of the Loan Facility, the Company drew down USD 25.0 million (EUR 22.3 million) on January 31, 2022 and will have access to a second tranche of USD 20.0 million (EUR 17.9 million) upon achievement prior to July 31, 2023, of product revenue from our diagnostics and pharmaceutical segments of at least USD 50.0 million (EUR 44.7 million) calculated on a trailing twelve month basis as of the last day of any fiscal month. The Loan Facility also includes covenants such that the Group is required to maintain product revenue, calculated as of the last day of each fiscal quarter and on a trailing twelve month basis as of such date, of at least EUR 30.0 million for any fiscal quarter prior to obtaining the second tranche and EUR 40.0 million for any fiscal quarter on or after obtaining the second tranche. Both tranches mature on January 29, 2027 with amortized repayments commencing March 1, 2025. The loans extended under the Loan Facility bear monthly interest payments at an interest rate of 7.93% per annum plus the 1-month CME Term SOFR reference rate as published by the CME Group Benchmark Administration Limited (subject to a floor of 0.07%). As security for the Borrowers’ obligations under the Loan Facility, the Borrowers granted the lenders thereunder a first priority security interest on all of each Borrower’s assets.

The Loan Facility is initially recognized at fair value minus transaction costs and subsequently carried at amortized cost measured using the effective interest rate method. The transaction costs deducted from the fair value of the Loan Facility at initial recognition was EUR 648k. The effective interest rate used for amortized cost calculation of the Facility Loan is 10.51%.

As of March 31, 2022, short-term cash deposits of EUR 938k (December 31, 2021: EUR 938k) were used to secure the secured bank loan outstanding (see Note 9 – Cash and short-term deposits).

The following table is based on the original terms and conditions:

Conditions and statement of liabilities

The outstanding interest-bearing liabilities as of March 31, 2022 and December 31, 2021 have the following conditions:


				Mar 31, 2022		Dec 31, 2021
				Nominal	Carrying	Nominal	Carrying
in EUR k	Currency	Nominal interest rate	Maturity	amount	amount	amount	amount
						Revised	Revised
Secured bank loan	EUR	2.95%	2017‑22	301	301	505	505
Secured bank loan	USD	7.93%	2022-27	22,348	21,890	—	—
Bank overdrafts	EUR	4.75%	Rollover	499	499	499	499
Bank overdrafts	EUR	3.75%	Rollover	2,372	2,372	2,329	2,329
Bank overdrafts	EUR	4.50%	Rollover	402	402	482	482
Lease liabilities**	EUR	2.1%-3.5%*, 5.4%-9.1%	2017-31	17,493	17,493	18,724	18,724
Total interest‑bearing financial liabilities				43,415	42,957	22,539	22,539

* represents the incremental borrowing rate of the Group at the commencement of the leases

** Lease liabilities as of December 31, 2021 has been revised. Refer to Note 2.2 – Revision of selected

assets and liabilities in the consolidated statement of financial position and selected income and expenses in the

consolidated statement of comprehensive loss.

The bank overdrafts of EUR 2,372k as of March 31, 2022 (December 31, 2021: EUR 2,329k) were secured by short-term deposits with a carrying amount of EUR 2,500k (December 31, 2021: EUR 2,500k) (see Note 9 – Cash and short-term deposits). The other bank overdrafts of EUR 901k (December 31, 2021: EUR 981k) were secured over two short-term deposits with a carrying amount of EUR 500k each (see Note 9 – Cash and short-term deposits).

11.2Trade payables and other liabilities


in EUR k	Mar 31, 2022	Dec 31, 2021
Trade payables	5,897	11,252
Government grants (deferred income)	9,023	9,396
Contract liabilities	2,166	4,842
Warrants liability	2,603	—
Others	12,393	14,632
Trade payables and other liabilities	32,082	40,122
Non‑current	10,109	8,028
Current	21,973	32,094

Government grants mainly include investment-related government grants. These were received for the purchase of certain items of property, plant and equipment for the research and development facilities in Mecklenburg-Western Pomerania, including the Rostock facility. The grants were issued in the form of investment subsidies as part of the joint federal and state program, "Verbesserung der regionalen Wirtschaftsstruktur" (improvement of the regional economic structure) in connection with funds from the European Regional Development Fund. No additional grants were received during the three months ended March 31, 2022 that are related to the purchase of certain items of property, plant and equipment (the three months ended March 31, 2021: EUR nil).

On January 31, 2022, pursuant to a securities purchase agreement and a warrant agreement, each signed with certain investors, the Group received EUR 15.0 million in exchange for the issuance of an aggregate of 4,479,088 common shares at a price per share of USD 3.73 (EUR 3.35) and warrants initially exercisable for the purchase of up to an aggregate of 1,343,727 additional common shares at an initial exercise price per common share of USD 7.72. The warrants are exercisable immediately as of the date of issuance and will expire on December 31, 2026. Based on the

fair value per share at the issuance date, the Group recognized the warrants as liabilities in the amount of USD 3.2 million (EUR 2.8 million). The fair value of warrants decreased from EUR 2.11 per warrant as of January 31, 2022 to EUR 1.93 per warrant as of March 31, 2022. The result is a decrease in fair value of warrant liabilities of EUR 238k for the three-month period ended March 31, 2022.

The fair value of the warrants was estimated at the date of issuance date using the Black-Scholes option pricing model. The key assumptions used to derive the warrants value are set out below:


	Mar 31, 2022	Jan 31, 2022
Exercise price (USD)	7.72	7.72
Share price at grant date (USD)	4.21	4.42
Volatility (%)	80	80
Risk-free interest rate (%)	1.63	1.65
Dividend yield (%)	-	-
Time to maturity	4.75	4.9

In addition, other liabilities include a provision for outstanding invoices of EUR 2,400k (December 31, 2021: EUR 4,978k), personnel-related liabilities for vacation and bonuses totaling EUR 4,031k (December 31, 2021: EUR 4,812k), a VAT payable of EUR nil (December 31, 2021: EUR 905k), as well as liabilities for wage and church tax of EUR 755k (December 31, 2021: EUR 1,040k).

Share-based payments

3 Months Ended

Mar. 31, 2022

Share-based payments

Share-based payments

12 Share-based payments

Expenses from share-based payment arrangements

During the three months ended March 31, 2022 and March 31, 2021, the following share-based payment arrangements existed leading to the expenses included in general administrative expenses for services received during the respective periods:


	For the three months ended March 31
in EUR k	2022	2021
Expenses arising from equity-settled share-based payment transactions
- Grants to management board and employees	470	429
- Grants to new CEO	113	799
- Supervisory board grant, including ESOP 2019	415	814
- Forfeiture of management board grants	(179)	—
- Expected forfeiture of management board grants	(2,775)	—
Total expenses arising from share‑based payment transactions	(1,957)	2,042

Share-based award activity

A detailed description of the Company’s share-based payment arrangements is included in Note 20 of the Group’s annual consolidated financial statements for the year ended December 31, 2021. During the three months ended March 31, 2022 there were no changes to the terms and conditions of the Company’s share-based payment arrangements.

The following table presents a summary the Company’s share-based payment arrangement activity for the three months ended March 31, 2022.


	ESOP 2017		2019-2022 awards ⁽¹⁾
Number of awards (options and restricted stock units "RSUs")	Number	WAEP	Number of options	WAEP (USD)	Number of RSUs	WAEP
Outstanding as of January 1, 2022	357,440	0.12	185,077	11.76	1,803,968	—
Granted during the year(1)	—	0.12	—	—	647,056	—
Exercised during the year	—	0.12	—	—	(34,498)	—
Forfeited during the year	—	0.12	—	—	(60,340)
Expected forfeited during the year	—	0.12	—	—	(754,572)
Outstanding as of March 31, 2022	357,440	0.12	185,077	11.76	1,601,614	—
Vested as of March 31, 2022	357,440		115,758		448,144
Exercisable as of March 31, 2022	357,440		115,758		448,144

_____________________________________

(1)

The granted and outstanding options and RSUs do not include the number of RSUs and options to be granted to certain supervisory board members annually in 2022 and thereafter, as these depend on the trailing volume-weighted average stock price of the Company.

The option and RSUs for the years 2019-2021 as reported in the table above reflect the activity related to the share-based payment awards under ESOP 2019, awards for management board, new CEO awards in 2022, and awards for supervisory board and employees.

Grants awarded

During the three months ended March 31, 2022 the following awards were granted:


Award Type (2019 Plan)	Market/ Performance Based Vesting Conditions	Number of Awards	Vesting Conditions	Expiration Date
RSUs	No	166,667	Vest in four equal tranches over a four-year period on each anniversary of the grant date (starting February 1, 2023)	10th anniversary of Grant Date
RSUs	Yes	174,394	Vest in four equal tranches over a four-year period on each anniversary of the grant date (starting February 1, 2023)	10th anniversary of Grant Date
RSUs	Yes	Up to 275,000	Vest in full after a change of control of the Group	10th anniversary of Grant Date
RSUs	No	30,995	Vest in four equal tranches over a four-year period on each anniversary of the grant date (starting January 1, 2023)	10th anniversary of Grant Date

New CEO Awards

On February 1, 2022, the CEO was awarded 174,394 initial performance RSUs subject to time-vesting and performance-vesting (“Performance-vested RSUs”), 166,667 initial time-vested RSUs subject to only time-vesting (“Time-vested RSUs”), and a number of RSUs equal to CHF 200,000 divided by the VWAP calculated as of the date of grant and 44,444 annual RSUs (together, “Annual RSUs”). All RSUs have a maturity of 10 years, are settled with ordinary shares and have no exercise price. In case of a termination of the service agreement by the CEO, all unvested RSUs will be forfeited to the extent they have remained unvested following the expiration of a 12 month period after termination.

Performance-vested RSUs also have a market condition that 50% of the Performance-vested RSUs vest only if the VWAP exceeds USD 12 and the remaining 50% of the Performance-vested RSUs vest if the VWAP exceeds USD 15. The Time-vested RSUs are not subject to any performance conditions, so their fair value equals the share price at grant date (after deduction of expected dividends during the respective vesting period, if any). The fair value for the Performance-vested RSUs is calculated by using an appropriate option pricing model (as described below) as these RSUs are subject to a market performance condition. Both Performance-vested RSUs and Time-vested RSUs vest over four years in four equal installments after the grant date and are recognized using the graded vesting method.

The fair value of the Performance-vested RSUs as of the grant date was determined using a Monte Carlo simulation model. The Monte Carlo simulation model utilizes multiple input variables to estimate the probability that market conditions will be achieved. The key assumptions used to derive the Performance-vested RSUs value are set out below:



	Tranche 1	Tranche 2
Share price at grant date (USD)	4.42	4.42
Fair value	2.10	1.60
Vesting hurdle	12	15
Date to reach vesting hurdle	January 1, 2024	January 1, 2024
Expected volatility	80%	80%
Risk-free rate	1.1	1.1
Time to vesting hurdle year	1.91	1.91
Dividend yield	nil	nil

With regard to the Annual RSUs, the CEO will receive an annual number of RSUs, starting from 2023, that will vest in four equal annual installments. Although the allocation of RSUs will be done in the future, the CEO must stay with Centogene during the period until the allocation of an annual grant of RSUs. Since these RSUs include a service condition, expenses regarding the services received are recognized starting from February 1, 2022. The CEO’s service agreement does not specify any end date for granting such annual RSUs, therefore the Company estimates the duration of her service period as four years, which is the duration of the CEO’s appointment by the Supervisory Board. The fair value of each grant of Annual RSUs is measured at each reporting date until the respective grant date is reached and the expenses are adjusted to this new fair value.

In the event of a change in control of the Company, all granted RSUs will vest immediately including a maximum of 275,000 additional RSUs (the “M&A RSUs”) which have the same grant date as the Time-vested RSUs and Performance-vested RSUs. The number of M&A RSU will be determined based on the share price at the occurrence of a change of control. Accordingly, the CEO will receive 200,000 M&A RSUs if the three-month VWAP prior to change of control is between USD 5 and USD 15 and 275,000 M&A RSUs if it is more than USD 15.

M&A RSUs are already promised within the service agreement, therefore, the grant date is the same as for the Time-vested RSUs and Performance-vested RSUs. This is also the date on which the fair value of the M&A RSUs were determined using a Black-Scholes-Merton model in the amount of EUR 156k. However, since the M&A RSUs will vest only if there is an occurrence of a change of control, which is not deemed probable by management in the foreseeable future, the Group did not account for these RSUs.

The remaining 30,995 RSUs were granted to management, subject to the terms of the 2019 Plan, the applicable award agreements and the terms specified in the authorization from the Supervisory Board for this purpose. The RSUs will vest in four equal tranches over a four-year period starting January 1, 2023. The grant date fair value of these grants will be recognized in profit or loss over the service period by using the graded approach.

The 30,995 RSUs referred to above have no performance-based vesting conditions and are to be settled in shares and expire on the 10th anniversary of the grant date.

The fair value of the 30,995 RSUs is based on the observed value of the underlying shares. As no dividend payments are expected over the vesting period, no further adjustment is required. The weighted average fair value of RSUs granted under the 2019 Plan during the three months ended March 31, 2022 was USD 3.23.

Exercises

During the three months ended March 31, 2022, 34,498 RSUs related to the 2020 management board and employment grant were exercised. The weighted average share price at the date of exercise was USD 4.78.

Forfeitures

On February 1, 2022, Andrin Oswald (the “Former CEO”) stepped down from his position and signed a separation agreement. Pursuant to his separation agreement, all unvested RSUs held by the Former CEO under the Company’s long term incentive plan continued to vest in accordance with their terms through the date of his termination on April 30, 2022. However, the number of RSUs he would receive would not exceed 62,284 RSUs. As a result, 69,428 RSUs were vested and the remaining unvested RSUs granted to the Former CEO were forfeited on the termination date as of April 30, 2022. Since the Former CEO has a right to only 62,284 RSUs, the remaining 7,144 RSUs from the total vested RSUs were cancelled. Expenses related to total unvested RSUs in the amount of EUR 2,775k that had been recognized in the financial statements in the previous periods were reversed during the three-month period ended March 31, 2022. This amount excludes the 69,428 RSUs vested, of which 62,284 RSUs vested pursuant to his separation agreement and 7,144 RSUs were cancelled.

On February 7, 2022, the Company announced the resignation of René Just as CFO effective March 31, 2022. According to his separation agreement signed on the same date, all unvested RSUs granted to Mr. Just as of March 31, 2022 were forfeited automatically without compensation for the loss of such RSUs. Since none of the RSUs granted to Mr. Just were vested, total RSUs in the amount of EUR 179k that had been recognized in the financial statements in the previous periods were reversed during the three-month period ended March 31, 2022.

Financial instruments at fair value

3 Months Ended

Mar. 31, 2022

Financial instruments at fair value

Financial instruments at fair value

13 Financial instruments at fair value

Classifications and fair values

The fair values of the Company’s cash and cash equivalents, accounts receivable and trade and other payables approximate their carrying values because of the short-term nature of these instruments.

Except for the warrant liability, the Group does not carry any financial instruments at fair value through profit and loss. The fair value of non-current loans is EUR 21,890k as of March 31, 2022. (December 31, 2021: EUR nil).

IFRS 13 establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value as follows:

Level 1 - quoted prices (unadjusted) in active markets for identical assets or liabilities;

Level 2 - inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly (i.e. as prices) or indirectly (i.e. derived from prices); and

Level 3 - inputs for the asset or liability that are not based on observable market data (unobservable inputs).

The following table shows the fair values of financial instruments as of March 31, 2022, including their level in the fair value hierarchy. It does not include fair value information for financial assets and financial liabilities not measured at fair value if the carrying amount is a reasonable approximation of fair value:


in EUR k	Level 1	Level 2	Level 3	Total
Non-current loans	-	21,890	-	21,890
Warrants liability	-	-	2,603	2,603

As of March 31, 2021, carrying amount of all financial assets or financial liabilities approximated their fair value.

Net gain recognized in the interim condensed consolidated statements of comprehensive loss, within changes in fair value of warrants, from the warrant liability fair value measurement differences was EUR 238k for the three months ended March 31, 2022.

The valuation techniques used in measuring level 2 & level 3 fair value for financial instruments in the interim condensed consolidated statement of financial position, as well as the significant unobservable inputs used, were as follows:

The fair value of the warrant liabilities, recognized as non-current financial liability at FVTPL, was calculated by applying a Black-Scholes option pricing model. This model uses the Centogene’s share price and the share price volatility as material input factors. The volatility is considered as material unobservable input factor (Level 3).

-	The fair value of non-current loans was calculated using the nominal amount less transaction costs and carried at amortized cost of €21,890k.

The table below summarizes the profit or loss impact on the fair values of Level 3 instruments, warrant liabilities, by changing the significant unobservable input factors.


	March 31, 2022
in EUR k	increase	decrease
Expected volatility (movement +/- 5%)	3,031	2,641

Financial risk management

3 Months Ended

Mar. 31, 2022

Financial risk management

Financial risk management

14 Financial risk management

The Group is exposed to certain financial risks which were disclosed in detail in the financial statements as of and for the year ended December 31, 2021. The Group’s financial risk management objective is to monitor and manage the financial risks relating to the operations of the Group. These risks include market risk (including currency risk and interest rate risk), credit risk and liquidity risk. In order to minimize the effect of financial risks, the Group invests time and resources to identify and evaluate the uncertainty of the market to mitigate risk exposures.

Currency risk

The Group is exposed to currency risk in cases where contracts are concluded in foreign currencies. The vast majority of goods delivered and services the Company provided, including those for international customers, are invoiced in euro. During the three months ended March 31, 2022, the Group undertook transactions denominated in foreign currencies such as warrant liabilities and non-current loans; consequently, was exposed to the exchange rate fluctuations.

The following table presents the net foreign currency exposure of the Group as of March 31, 2022 and December 31, 2021:


	March 31, 2022
in EUR k	USD	INR
Trade receivables and other assets	3,849	13
Trade payables and other liabilities	(2,377)	-
Financial liabilities	(21,890)	-
Net exposure	(20,418)	13

	Dec 31, 2021
in EUR k	USD	INR
Trade receivables and other assets	4,635	8
Trade payables and other liabilities	(2,394)	(4)
Net exposure	2,241	4

Sensitivity analysis

The following tables demonstrate the sensitivity at the end of the reporting period to a reasonably possible change in the USD exchange rates, with all other variables held constant, of the Group’s earnings before tax and equity movement. The Group’s exposure to foreign currency risk for all other currencies is not material.


	Earnings before tax		Equity
in EUR k	5% increase	5% decrease	5% increase	5% decrease
March 31, 2022	953	(1,053)	953	(1,053)
December 31, 2021	(101)	112	(101)	112

Interest rate risk

Interest bearing liabilities with floating interest rates exist for non-current loans as of March 31, 2022.

The following sensitivity analyses has been determined based on the exposure to interest rates at the reporting date. For the floating rate liabilities, the analysis is prepared assuming the amount of liability outstanding at the reporting date was outstanding for the whole period. In accordance with the relevant loan agreement, the interest rate cannot be lower than the determined interest rate and therefore the analysis has only been performed for the scenario where interest rate increases.

If interest rates had been 1.0 percentage point higher and all other variables were held constant, the Group’s earning before tax would decrease by EUR 41k for the three months ended March 31, 2022 (December 31, 2021: nil).

Commitments

3 Months Ended

Mar. 31, 2022

Commitments

Commitments

15 Commitments

Future payments for non-cancellable leases

The Group has various lease contracts in relation to the expansion of the Rostock headquarters. The future lease payments and utilities for these non-cancellable lease contracts are EUR 113k within one year, EUR 2,373k within five years and EUR 4,056k thereafter (December 31, 2021: EUR 107k, EUR 2,370k and EUR 4,219k respectively).

The Group has various non-cancellable lease contracts of office equipment and storage spaces which had a lease term of less than 12 months or were related to leases of low-value assets, and therefore the short-term lease recognition exemption was applied to these contracts. The future lease payments for these non-cancellable lease contracts are EUR 39k within one year (December 31, 2021: EUR 44k) and EUR 40k within five years (December 31, 2021: EUR 49k).

Future payment obligations

As of March 31, 2022, the Group concluded agreements with suppliers, for goods and services to be provided subsequent to March 31, 2022 with a total payment obligation of approximately EUR 3,126k (December 31, 2021: EUR 6,620k).

Contingent Liabilities

3 Months Ended

Mar. 31, 2022

Contingent Liabilities

Contingent Liabilities

16 Contingent Liabilities

In May 2016, the Company was informed in writing by the Universitair Medisch Centrum Utrecht ("UMCU") that a claim had been initiated against UMCU regarding a prenatal diagnostic test that the Company conducted at their request which failed to identify a specific mutation present in a patient. On October 1, 2018, the UMCU and Neon Underwriting Limited formally filed a legal claim in the local court in Rostock, Germany against the Company alleging that the Company’s negligence in performing the test resulted in the misdiagnosis of the patient. UMCU is seeking recovery for compensatory damages as a result of the alleged misdiagnosis. By court order of November 8, 2018, the Regional Court of Rostock set the amount in dispute at EUR 880k.

On November 12, 2018, the Company submitted a notice to the Regional Court of Rostock of the intention to defend against the claim. On January 3, 2019, the Company filed a motion to dismiss in which the Company denied the merits of the claim. UMCU and Neon Underwriting Limited responded to this motion on March 15, 2019 with a statement of reply, and the parties made several court filings setting out their arguments since. By order dated June 3, 2019, the Regional Court of Rostock provided a first set of questions to be answered by an expert witness.

As of December 31, 2020, the amount in dispute was EUR 1.3 million. The matter was assigned to a new judge, due to the illness of the prior judge, and the decision to appoint the recommended expert witness is still pending. Since then, several potential experts were approached by the court but eventually declined to prepare an expert witness report due to the possibility of bias.

The Company intends to continue to rigorously defend its position and considers that it is not probable the legal claim towards the Company will be successful and as a result has not recognized a provision for this claim as of December 31, 2021. In addition, in case a settlement would be required, the Company believes that the corresponding liability will be fully covered by the respective existing insurance policies.

On August 7, 2021, our partnering laboratory physician and a key executive officer of ours, Prof. Dr. Peter Bauer was informed in writing by the Public Prosecutor's Office in Fulda that a criminal investigation had been initiated against him regarding allegedly false billing statements submitted to the Association of Statutory Health Insurance Physicians in Hessen (Kassenärztliche Vereinigung Hessen). The aggregate amount in question was EUR 42,268.50. The investigation and claims were subsequently dropped in January 2022.

Subsequent Events

3 Months Ended

Mar. 31, 2022

Subsequent Events

Subsequent Events

17 Subsequent Events

Leadership transition

On May 2, 2022, Volkmar Weckesser resigned from his duties as the Chief Information Officer effective as of May 3, 2022. According to the separation agreement signed on the same date, his service agreement will terminate on June 29, 2022 (the “Termination Date”). All 33,773 vested options related to the pre-IPO program held by Mr. Weckesser that have not yet been exercised and settled as of the Termination Date must be exercised and settled in accordance with their terms within 12 months following the Termination Date. The 10,000 RSUs held by Mr. Weckesser that were granted in 2020 and that remained unvested as of the Termination Date will fully vest and the 10,000 options that remained unvested will be forfeited without compensation for the loss of such options and RSUs. The 20,000 RSUs and 15,000 options held by Mr. Weckesser that were granted in 2021 and that remained unvested as of the Termination Date will be forfeited automatically without compensation for the loss of such options and RSUs.

On June 27, 2022, the Group announced the appointment of Jose Miguel Coego Rios as the Managing Director and Chief Financial Officer of the Company, effective June 22, 2022. The CFO and the Group entered into an award agreement pursuant to which the CFO will receive certain RSUs, which have no exercise price. According to the agreement, the RSUs are awarded in two forms as 58,132 initial performance RSUs subject to performance vesting and 55,556 initial time-vested RSUs. Initial performance RSUs vest in two equal installments and time vested RSUs vest in four equal installments after the grant date of May 27, 2022. Both awards have an expiration date of May 27, 2032; however, initial performance RSUs that do not vest by February 1, 2024 will expire on February 2, 2024.

Effective June 22, 2022, each member of the Supervisory Board will receive an award of options and RSUs in ordinary shares (such options and RSUs collectively, the "LTIs") with a value of EUR 140k multiplied by the LTI Factor as defined in the incentive agreement. In addition to this, the chairman and vice-chairman of the Supervisory Board, the chairman of the Audit Committee and the chairman of the Compensation Committee will receive additional LTIs with a value of EUR 105k, EUR 70k, EUR 70k and EUR 14k, each multiplied by the LTI Factor, respectively. Each LTI consists of RSUs for 75% of the value of the LTI and options for 25% of the value of the LTI. The LTIs vest in four equal instalments on each relevant anniversary of the grant date or in full upon the occurrence of a change of control with a maturity date of 10 years. The LTIs will be settled in shares, are not subject to any performance criteria and have no exercise price. The LTIs will be granted retrospectively for the preceding financial year following the audit of the Company's annual financial statements for such financial year.

These unaudited interim condensed consolidated financial statements were approved by management on July 15, 2022.

Basis of preparation (Policies)

3 Months Ended

Mar. 31, 2022

Basis of preparation

Discontinued operations

Discontinued operations

Warrants

Warrants

Revision of selected assets and liabilities in the consolidated statement of financial position and selected income and expenses in the consolidated statement of comprehensive loss

2.2Revision of selected assets and liabilities in the consolidated statement of financial position and selected income and expenses in the consolidated statement of comprehensive loss

The changes to the consolidated statement of financial position as of December 31, 2021 are as follows:


in EUR k	Dec 31, 2021 (as previously reported)	Adjustment	Dec 31, 2021 (revised)
Property, plant & equipment	8,147	1,317	9,464
Non-current Assets	39,217	1,317	40,534
Total assets	90,694	1,317	92,011

Retained earnings and other reserves	(109,295)	1,590	(107,705)
Equity	27,503	1,590	29,093

Lease liabilities	15,588	(194)	15,394
Non-current liabilities	23,695	(194)	23,501
Lease liabilities	3,409	(79)	3,330
Current liabilities	39,496	(79)	39,417
Total Liabilities	63,191	(273)	62,918

The changes to the consolidated statements of comprehensive income for the year ended December 31, 2021 are as follows:


	Dec 31, 2021 (as previously reported)	Adjustment	Dec 31, 2021 (revised)
Revenue	189,923	-	189,923
Cost of sales	161,765	(1,317)	160,448
Gross profit	28,158	1,317	29,475
Research and development expenses	19,297	-	19,297
General administrative expenses	46,739	-	46,739
Selling expenses	9,860	-	9,860
Impairment of financial assets	1,140	-	1,140
Other operating income	2,936	273	3,209
Other operating expenses	86	-	86
Operating loss	(46,028)	1,590	(44,438)
Loss for the year	(46,852)	1,590	(45,262)
Total comprehensive loss	(46,309)	1,590	(44,719)
Loss per share- Basic and diluted (in EUR)	(2.06)	0.08	(1.98)

Basis of preparation (Tables)

3 Months Ended

Mar. 31, 2022

Basis of preparation

Schedule of changes to the statement of financial position


in EUR k	Dec 31, 2021 (as previously reported)	Adjustment	Dec 31, 2021 (revised)
Property, plant & equipment	8,147	1,317	9,464
Non-current Assets	39,217	1,317	40,534
Total assets	90,694	1,317	92,011

Retained earnings and other reserves	(109,295)	1,590	(107,705)
Equity	27,503	1,590	29,093

Lease liabilities	15,588	(194)	15,394
Non-current liabilities	23,695	(194)	23,501
Lease liabilities	3,409	(79)	3,330
Current liabilities	39,496	(79)	39,417
Total Liabilities	63,191	(273)	62,918

Schedule of changes to the statements of comprehensive income


	Dec 31, 2021 (as previously reported)	Adjustment	Dec 31, 2021 (revised)
Revenue	189,923	-	189,923
Cost of sales	161,765	(1,317)	160,448
Gross profit	28,158	1,317	29,475
Research and development expenses	19,297	-	19,297
General administrative expenses	46,739	-	46,739
Selling expenses	9,860	-	9,860
Impairment of financial assets	1,140	-	1,140
Other operating income	2,936	273	3,209
Other operating expenses	86	-	86
Operating loss	(46,028)	1,590	(44,438)
Loss for the year	(46,852)	1,590	(45,262)
Total comprehensive loss	(46,309)	1,590	(44,719)
Loss per share- Basic and diluted (in EUR)	(2.06)	0.08	(1.98)

Revenues from contracts with customers (Tables)

3 Months Ended

Mar. 31, 2022

Revenues from contracts with customers

Schedule of geographical information


in EUR k	For the three months ended March 31, 2022
	Pharmaceutical	Diagnostics	Total
Rendering of services	3,047	7,092	10,139
Sales of goods	188	—	188
Total Revenues from contracts with external customers	3,235	7,092	10,327

Recognized over time	3,047	7,092	10,139
Recognized at a point in time	188	—	188
Total Revenues from contracts with external customers	3,235	7,092	10,327

Geographical information
Europe	18	1,421	1,439
—Germany*	—	78	78
—Netherlands**	—	7	7
Middle East	58	4,033	4,091
—Saudi Arabia#	—	2,421	2,421
North America	3,145	625	3,770
—United States#	3,145	604	3,749
Latin America	14	715	729
Asia Pacific	—	298	298
Total Revenues from contracts with external customers	3,235	7,092	10,327


in EUR k	For the three months ended March 31, 2021
	Pharmaceutical	Diagnostics	Total
Rendering of services	3,393	6,383	9,776
Sales of goods	205	—	205
Total Revenues from contracts with external customers	3,598	6,383	9,981

Recognized over time	3,393	6,383	9,776
Recognized at a point in time	205	—	205
Total Revenues from contracts with external customers	3,598	6,383	9,981

Geographical information
Europe	149	1,214	1,363
—Germany*	—	53	53
—Netherlands**	—	2	2
Middle East	29	4,135	4,164
—Saudi Arabia#	—	2,683	2,683
North America	3,405	464	3,869
—United States#	3,405	403	3,808
Latin America	15	410	425
Asia Pacific	—	160	160
Total Revenues from contracts with external customers	3,598	6,383	9,981

* country of the incorporation of Centogene GmbH

** country of the incorporation of Centogene N.V.

# countries contributing more than 10% of the Group’s total consolidated revenues for the three months ended March 31, 2022 and 2021, respectively.

Segment information (Tables)

3 Months Ended

Mar. 31, 2022

Segment information

Schedule of reconciliation of segment Adjusted EBITDA to Group loss before taxes from continuing operations


in EUR k	For the three months ended March 31, 2022
	Pharmaceutical	Diagnostics	Corporate	Total
Total Revenues from contracts with external customers	3,235	7,092	—	10,327

Adjusted EBITDA	1,099	812	(11,964)	(10,053)

Capital Expenditures
Additions to property, plant and equipment and right-of-use assets	—	—	79	79
Additions to intangible assets	29	—	15	44

Other segment information
Depreciation and amortization	127	441	1,795	2,363
Research and development expenses	—	—	4,614	4,614


in EUR k	For the three months ended March 31, 2021
	Pharmaceutical	Diagnostics	Corporate	Total
Total Revenues from contracts with external customers	3,598	6,383	—	9,981

Adjusted EBITDA	1,497	1,054	(12,020)	(9,469)

Capital Expenditures
Additions to property, plant and equipment and right-of-use assets	6	234	314	554
Additions to intangible assets	322	—	650	972

Other segment information
Depreciation and amortization	414	406	1,539	2,359
Research and development expenses	—	—	4,335	4,335

Reconciliation of segment Adjusted EBITDA to Group loss before taxes from continuing operations


For the three months ended March 31	2022	2021
Reported segment Adjusted EBITDA	1,911	2,551
Corporate expenses	(11,964)	(12,020)
	(10,053)	(9,469)
Share-based payment (true-up)/ expenses (Note 12)	1,957	(2,042)
Depreciation and amortization	(2,363)	(2,359)
Operating loss from continuing operations	(10,459)	(13,870)
Financial costs, net	(620)	(259)
Loss before taxes from continuing operations for the three months ended March 31	(11,079)	(14,129)

Other income and expenses (Tables)

3 Months Ended

Mar. 31, 2022

Other income and expenses

Schedule of other operating income


	For the three months ended March 31
in EUR k	2022	2021
Government grants	553	340
Others	180	26
Total other operating income	733	366

Schedule of other operating expenses


	For the three months ended March 31
in EUR k	2022	2021
Currency losses	1	34
Total other operating expenses	1	34

Discontinued operations (Tables)

3 Months Ended

Mar. 31, 2022

Discontinued operations

Schedule Of Continuing And Discontinued Operations in the consolidated statements of comprehensive income and consolidated statements of cash flows


	For the three months ended March 31
	2022	2021
Results of discontinued operations
Revenue	19,463	54,979
Cost of sales	15,200	44,547
Gross profit	4,263	10,432
General administrative expenses	302	999
Selling expenses	7	193
Other operating income	706	-
Operating income	4,660	9,240
Financial costs, net	46	-
Income before taxes	4,614	9,240
Income tax expense	13	-
Income for the period	4,601	9,240
Total comprehensive income, attributable to equity holders of the parent	4,601	9,240
Net income per share - Basic and diluted (in EUR)	0.20	0.41

Cash flow from discontinued operations
Net cash flow from operating activities	2,835	8,962
Net cash flow from/ (used in) investing activities	575	(1,770)
Net cash flow used in financing activities	(409)	(275)

Trade receivables and other assets (Tables)

3 Months Ended

Mar. 31, 2022

Trade receivables and other assets.

Summary of trade receivables and other assets


in EUR k	Mar 31, 2022	Dec 31, 2021
Non‑current
Other assets - Rental deposits	2,922	2,922
Other assets – Others	50	50
	2,972	2,972
Current
Trade receivables, net	18,209	21,065
Contract assets, net	2,916	3,272
Other assets	5,443	5,453
	26,568	29,790
Total non-current and current trade receivables and other assets	29,540	32,762

Summary of expected credit loss rate on total gross trade receivables and contract assets


in EUR k	Mar 31, 2022		Dec 31, 2021
Not past due	9,355		17,978
Past due 1-30 days	2,743		1,476
Past due 31-90 days	6,487		2,596
Past due more than 90 days	8,403		8,004
Total gross amount of trade receivables and contract assets	26,988		30,054

Expected credit loss rate
Not past due	1.5	%	0.9	%
Past due 1-30 days	6.9	%	7.7	%
Past due 31-90 days	4.8	%	11.7	%
Past due more than 90 days	62.1	%	64.1	%
Expected credit loss rate on total gross trade receivables and contract assets	21.7	%	19.0	%

Expected credit loss	5,863		5,717

Financial liabilities (Tables)

3 Months Ended

Mar. 31, 2022

Financial liabilities

Schedule of interest-bearing liabilities


in EUR k	Mar 31, 2022	Dec 31, 2021
		Revised
Non‑current liabilities
Non‑current portion of secured bank loans	21,890	—
Total non‑current loans	21,890	—
Lease liabilities*	14,540	15,394
Total non‑current liabilities	36,430	15,394

Current liabilities
Current portion of secured bank loans	301	505
Bank overdrafts	3,273	3,310
Total current loans	3,574	3,815
Current portion of lease liabilities*	2,953	3,330
Total current liabilities	6,527	7,145

Total non‑current and current liabilities	42,957	22,539

Schedule of outstanding interest-bearing liabilities


				Mar 31, 2022		Dec 31, 2021
				Nominal	Carrying	Nominal	Carrying
in EUR k	Currency	Nominal interest rate	Maturity	amount	amount	amount	amount
						Revised	Revised
Secured bank loan	EUR	2.95%	2017‑22	301	301	505	505
Secured bank loan	USD	7.93%	2022-27	22,348	21,890	—	—
Bank overdrafts	EUR	4.75%	Rollover	499	499	499	499
Bank overdrafts	EUR	3.75%	Rollover	2,372	2,372	2,329	2,329
Bank overdrafts	EUR	4.50%	Rollover	402	402	482	482
Lease liabilities**	EUR	2.1%-3.5%*, 5.4%-9.1%	2017-31	17,493	17,493	18,724	18,724
Total interest‑bearing financial liabilities				43,415	42,957	22,539	22,539

* represents the incremental borrowing rate of the Group at the commencement of the leases

** Lease liabilities as of December 31, 2021 has been revised. Refer to Note 2.2 – Revision of selected

assets and liabilities in the consolidated statement of financial position and selected income and expenses in the

consolidated statement of comprehensive loss.

Schedule of trade payables and other liabilities


in EUR k	Mar 31, 2022	Dec 31, 2021
Trade payables	5,897	11,252
Government grants (deferred income)	9,023	9,396
Contract liabilities	2,166	4,842
Warrants liability	2,603	—
Others	12,393	14,632
Trade payables and other liabilities	32,082	40,122
Non‑current	10,109	8,028
Current	21,973	32,094

Schedule of key assumptions used to derive warrants value


	Mar 31, 2022	Jan 31, 2022
Exercise price (USD)	7.72	7.72
Share price at grant date (USD)	4.21	4.42
Volatility (%)	80	80
Risk-free interest rate (%)	1.63	1.65
Dividend yield (%)	-	-
Time to maturity	4.75	4.9

Share-based payments (Tables)

3 Months Ended

Mar. 31, 2022

Share-based payments

Schedule of total expenses arising from sharebased payment transactions


	For the three months ended March 31
in EUR k	2022	2021
Expenses arising from equity-settled share-based payment transactions
- Grants to management board and employees	470	429
- Grants to new CEO	113	799
- Supervisory board grant, including ESOP 2019	415	814
- Forfeiture of management board grants	(179)	—
- Expected forfeiture of management board grants	(2,775)	—
Total expenses arising from share‑based payment transactions	(1,957)	2,042

Schedule of share option activity

The following table presents a summary the Company’s share-based payment arrangement activity for the three months ended March 31, 2022.


	ESOP 2017		2019-2022 awards ⁽¹⁾
Number of awards (options and restricted stock units "RSUs")	Number	WAEP	Number of options	WAEP (USD)	Number of RSUs	WAEP
Outstanding as of January 1, 2022	357,440	0.12	185,077	11.76	1,803,968	—
Granted during the year(1)	—	0.12	—	—	647,056	—
Exercised during the year	—	0.12	—	—	(34,498)	—
Forfeited during the year	—	0.12	—	—	(60,340)
Expected forfeited during the year	—	0.12	—	—	(754,572)
Outstanding as of March 31, 2022	357,440	0.12	185,077	11.76	1,601,614	—
Vested as of March 31, 2022	357,440		115,758		448,144
Exercisable as of March 31, 2022	357,440		115,758		448,144

_____________________________________

(1)

Summary of awards granted

During the three months ended March 31, 2022 the following awards were granted:


Award Type (2019 Plan)	Market/ Performance Based Vesting Conditions	Number of Awards	Vesting Conditions	Expiration Date
RSUs	No	166,667	Vest in four equal tranches over a four-year period on each anniversary of the grant date (starting February 1, 2023)	10th anniversary of Grant Date
RSUs	Yes	174,394	Vest in four equal tranches over a four-year period on each anniversary of the grant date (starting February 1, 2023)	10th anniversary of Grant Date
RSUs	Yes	Up to 275,000	Vest in full after a change of control of the Group	10th anniversary of Grant Date
RSUs	No	30,995	Vest in four equal tranches over a four-year period on each anniversary of the grant date (starting January 1, 2023)	10th anniversary of Grant Date

Performance Based RSUs

Share-based payments

Schedule of key assumptions used to derive the option value



	Tranche 1	Tranche 2
Share price at grant date (USD)	4.42	4.42
Fair value	2.10	1.60
Vesting hurdle	12	15
Date to reach vesting hurdle	January 1, 2024	January 1, 2024
Expected volatility	80%	80%
Risk-free rate	1.1	1.1
Time to vesting hurdle year	1.91	1.91
Dividend yield	nil	nil

Financial instruments at fair value (Tables)

3 Months Ended

Mar. 31, 2022

Financial instruments at fair value

Schedule of assets and liabilities that are measured at fair value on a recurring basis


in EUR k	Level 1	Level 2	Level 3	Total
Non-current loans	-	21,890	-	21,890
Warrants liability	-	-	2,603	2,603

Schedule of profit or loss impact on the fair values of Level 3 instruments


	March 31, 2022
in EUR k	increase	decrease
Expected volatility (movement +/- 5%)	3,031	2,641

Financial risk management (Tables)

3 Months Ended

Mar. 31, 2022

Financial risk management

Schedule of net foreign currency exposure

The following table presents the net foreign currency exposure of the Group as of March 31, 2022 and December 31, 2021:


	March 31, 2022
in EUR k	USD	INR
Trade receivables and other assets	3,849	13
Trade payables and other liabilities	(2,377)	-
Financial liabilities	(21,890)	-
Net exposure	(20,418)	13

	Dec 31, 2021
in EUR k	USD	INR
Trade receivables and other assets	4,635	8
Trade payables and other liabilities	(2,394)	(4)
Net exposure	2,241	4

Schedule of exchange rate sensitivity


	Earnings before tax		Equity
in EUR k	5% increase	5% decrease	5% increase	5% decrease
March 31, 2022	953	(1,053)	953	(1,053)
December 31, 2021	(101)	112	(101)	112

Basis of preparation (Details) € in Thousands	3 Months Ended		12 Months Ended
Basis of preparation (Details) € in Thousands	Mar. 31, 2022 EUR (€) shares	Mar. 31, 2021 EUR (€)	Dec. 31, 2021 EUR (€)	Mar. 31, 2022 $ / shares	Jan. 31, 2022 $ / shares shares
Disclosure of changes in accounting estimates [line items]
Number of securities called by warrants \| shares	1				1,343,727
Exercise price of warrants \| $ / shares				$ 7.72	$ 7.72
Property, plant and equipment	€ 7,674		€ 9,464
Other operating income	733	€ 366	3,209
Change
Disclosure of changes in accounting estimates [line items]
Depreciation expense			(1,317)
Other operating income (expense)			273
Lease liability			(273)
Property, plant and equipment			1,317
Other operating income			€ 273
Warrants
Disclosure of changes in accounting estimates [line items]
Share issue related cost	€ 68

Basis of preparation - Schedule of changes to the statement of financial position (Details) - EUR (€) € in Thousands	Mar. 31, 2022	Dec. 31, 2021	Mar. 31, 2021	Dec. 31, 2020
Disclosure of changes in accounting estimates [line items]
Property, plant and equipment	€ 7,674	€ 9,464
Non-current Assets	36,801	40,534
Total assets	108,102	92,011
Retained earnings and other reserves	(114,120)	(107,705)
Equity	32,806	29,093	€ 63,051	€ 65,777
Lease liabilities	14,540	15,394
Non-current liabilities	46,598	23,501
Lease liabilities	2,953	3,330
Current liabilities	€ 28,698	39,417
Total Liabilities		62,918
Previously Reported
Disclosure of changes in accounting estimates [line items]
Property, plant and equipment		8,147
Non-current Assets		39,217
Total assets		90,694
Retained earnings and other reserves		(109,295)
Equity		27,503
Lease liabilities		15,588
Non-current liabilities		23,695
Lease liabilities		3,409
Current liabilities		39,496
Total Liabilities		63,191
Change
Disclosure of changes in accounting estimates [line items]
Property, plant and equipment		1,317
Non-current Assets		1,317
Total assets		1,317
Retained earnings and other reserves		1,590
Equity		1,590
Lease liabilities		(194)
Non-current liabilities		(194)
Lease liabilities		(79)
Current liabilities		(79)
Total Liabilities		€ (273)

Basis of Preparation - Schedule of changes to the statements of comprehensive income (Details) - EUR (€) € / shares in Units, € in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021
Disclosure of changes in accounting estimates [line items]
Revenue	€ 10,327	€ 9,981	€ 189,923
Cost of sales	6,450	6,208	160,448
Gross profit	3,877	3,773	29,475
Research and development expenses	4,614	4,335	19,297
General administrative expenses	7,906	11,596	46,739
Selling expenses	2,394	1,949	9,860
Impairment of financial assets	154	95	1,140
Other operating income	733	366	3,209
Total other operating expenses	1	34	86
Operating loss	(10,459)	(13,870)	(44,438)
Loss for the period	(6,482)	(4,889)	(45,262)
Total comprehensive loss	€ (6,388)	€ (4,768)	€ (44,719)
Net loss per share - Continuing operations - Basic (in EUR)	€ (0.48)	€ (0.63)	€ (1.98)
Net loss per share - Continuing operations - Diluted (in EUR)	€ (0.48)	€ (0.63)	€ (1.98)
Previously Reported
Disclosure of changes in accounting estimates [line items]
Revenue			€ 189,923
Cost of sales			161,765
Gross profit			28,158
Research and development expenses			19,297
General administrative expenses			46,739
Selling expenses			9,860
Impairment of financial assets			1,140
Other operating income			2,936
Total other operating expenses			86
Operating loss			(46,028)
Loss for the period			(46,852)
Total comprehensive loss			€ (46,309)
Net loss per share - Continuing operations - Basic (in EUR)			€ (2.06)
Net loss per share - Continuing operations - Diluted (in EUR)			€ (2.06)
Change
Disclosure of changes in accounting estimates [line items]
Cost of sales			€ (1,317)
Gross profit			1,317
Other operating income			273
Operating loss			1,590
Loss for the period			1,590
Total comprehensive loss			€ 1,590
Net loss per share - Continuing operations - Basic (in EUR)			€ 0.08
Net loss per share - Continuing operations - Diluted (in EUR)			€ 0.08

Revenues from contracts with customers - Geographical information (Details) - EUR (€) € in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021
Disclosure of geographical areas
Rendering of services	€ 10,139	€ 9,776
Sales of goods	188	205
Total Revenues from contracts with external customers	10,327	9,981	€ 189,923
Europe
Disclosure of geographical areas
Total Revenues from contracts with external customers	1,439	1,363
-Germany
Disclosure of geographical areas
Total Revenues from contracts with external customers	78	53
-Netherlands
Disclosure of geographical areas
Total Revenues from contracts with external customers	7	2
Middle East
Disclosure of geographical areas
Total Revenues from contracts with external customers	4,091	4,164
-Saudi Arabia
Disclosure of geographical areas
Total Revenues from contracts with external customers	2,421	2,683
North America
Disclosure of geographical areas
Total Revenues from contracts with external customers	3,770	3,869
-United States
Disclosure of geographical areas
Total Revenues from contracts with external customers	3,749	3,808
Latin America
Disclosure of geographical areas
Total Revenues from contracts with external customers	729	425
Asia Pacific
Disclosure of geographical areas
Total Revenues from contracts with external customers	298	160
Recognized over time
Disclosure of geographical areas
Total Revenues from contracts with external customers	10,139	9,776
Recognized at a point in time
Disclosure of geographical areas
Total Revenues from contracts with external customers	188	205
Pharmaceutical
Disclosure of geographical areas
Rendering of services	3,047	3,393
Sales of goods	188	205
Total Revenues from contracts with external customers	3,235	3,598
Pharmaceutical \| Europe
Disclosure of geographical areas
Total Revenues from contracts with external customers	18	149
Pharmaceutical \| Middle East
Disclosure of geographical areas
Total Revenues from contracts with external customers	58	29
Pharmaceutical \| North America
Disclosure of geographical areas
Total Revenues from contracts with external customers	3,145	3,405
Pharmaceutical \| -United States
Disclosure of geographical areas
Total Revenues from contracts with external customers	3,145	3,405
Pharmaceutical \| Latin America
Disclosure of geographical areas
Total Revenues from contracts with external customers	14	15
Pharmaceutical \| Recognized over time
Disclosure of geographical areas
Total Revenues from contracts with external customers	3,047	3,393
Pharmaceutical \| Recognized at a point in time
Disclosure of geographical areas
Total Revenues from contracts with external customers	188	205
Diagnostics
Disclosure of geographical areas
Rendering of services	7,092	6,383
Total Revenues from contracts with external customers	7,092	6,383
Diagnostics \| Europe
Disclosure of geographical areas
Total Revenues from contracts with external customers	1,421	1,214
Diagnostics \| -Germany
Disclosure of geographical areas
Total Revenues from contracts with external customers	78	53
Diagnostics \| -Netherlands
Disclosure of geographical areas
Total Revenues from contracts with external customers	7	2
Diagnostics \| Middle East
Disclosure of geographical areas
Total Revenues from contracts with external customers	4,033	4,135
Diagnostics \| -Saudi Arabia
Disclosure of geographical areas
Total Revenues from contracts with external customers	2,421	2,683
Diagnostics \| North America
Disclosure of geographical areas
Total Revenues from contracts with external customers	625	464
Diagnostics \| -United States
Disclosure of geographical areas
Total Revenues from contracts with external customers	604	403
Diagnostics \| Latin America
Disclosure of geographical areas
Total Revenues from contracts with external customers	715	410
Diagnostics \| Asia Pacific
Disclosure of geographical areas
Total Revenues from contracts with external customers	298	160
Diagnostics \| Recognized over time
Disclosure of geographical areas
Total Revenues from contracts with external customers	€ 7,092	€ 6,383

Revenues from contracts with customers - Additional Information (Details) - Pharmaceutical Partner - Pharmaceutical - customer	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Revenue from contracts with customers
Number of customers	1
Revenue contributed as a percentage of Group's total revenues	19.00%	30.50%

Segment information - Information by operating segments (Details) - EUR (€) € in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021
Segment information
Total Revenues from contracts with external customers	€ 10,327	€ 9,981	€ 189,923
Adjusted EBITDA	(10,053)	(9,469)
Additions to property, plant and equipment and right-of-use assets	79	554
Additions to intangible assets	44	972
Other segment information
Depreciation and amortization	2,363	2,359
Research and development expenses	4,614	4,335	€ 19,297
Pharmaceutical
Segment information
Total Revenues from contracts with external customers	3,235	3,598
Diagnostics
Segment information
Total Revenues from contracts with external customers	7,092	6,383
Operating segment \| Pharmaceutical
Segment information
Total Revenues from contracts with external customers	3,235	3,598
Adjusted EBITDA	1,099	1,497
Additions to property, plant and equipment and right-of-use assets		6
Additions to intangible assets	29	322
Other segment information
Depreciation and amortization	127	414
Operating segment \| Diagnostics
Segment information
Total Revenues from contracts with external customers	7,092	6,383
Adjusted EBITDA	812	1,054
Additions to property, plant and equipment and right-of-use assets		234
Other segment information
Depreciation and amortization	441	406
Corporate
Segment information
Adjusted EBITDA	(11,964)	(12,020)
Additions to property, plant and equipment and right-of-use assets	79	314
Additions to intangible assets	15	650
Other segment information
Depreciation and amortization	1,795	1,539
Research and development expenses	€ 4,614	€ 4,335

Segment information - Reconciliation of segment Adjusted EBITDA to Group loss before taxes (Details) - EUR (€) € in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021
Segment information
Depreciation and amortization	€ (2,363)	€ (2,359)
Operating loss	(10,459)	(13,870)	€ (44,438)
Financial costs, net	(620)	(259)
Loss before taxes from continuing operations	(11,079)	(14,129)
Operating segment
Segment information
Reported segment Adjusted EBITDA	1,911	2,551
Reported segment Adjusted EBITDA after corporate expenses	(10,053)	(9,469)
Operating loss	(10,459)	(13,870)
Financial costs, net	(620)	(259)
Loss before taxes from continuing operations	(11,079)	(14,129)
Corporate
Segment information
Corporate expenses	(11,964)	(12,020)
Depreciation and amortization	(1,795)	(1,539)
Sharebased payment expenses
Segment information
Share-based payment (true-up)/ expenses (Note 12)	1,957	(2,042)
Depreciation and amortization
Segment information
Depreciation and amortization	€ (2,363)	€ (2,359)

Segment information - Additional information (Details) € in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2022 EUR (€) customer	Mar. 31, 2021 EUR (€)	Dec. 31, 2021 EUR (€)
Segment information and revenue from contracts with customers
Property, plant and equipment	€ 7,674		€ 9,464
Right-of-use assets	17,972		18,904
Revenue from contracts with customers	10,327	€ 9,981	189,923
-United States
Segment information and revenue from contracts with customers
Property, plant and equipment	132		147
Right-of-use assets	69		€ 137
Revenue from contracts with customers	3,749	3,808
-Germany
Segment information and revenue from contracts with customers
Revenue from contracts with customers	78	53
Pharmaceutical
Segment information and revenue from contracts with customers
Revenue from contracts with customers	€ 3,235	€ 3,598
Pharmaceutical \| Pharmaceutical Partner
Segment information and revenue from contracts with customers
Number of customers \| customer	1
Percentage of revenue	19.00%	30.50%
Pharmaceutical \| -United States
Segment information and revenue from contracts with customers
Revenue from contracts with customers	€ 3,145	€ 3,405

Other income and expenses - Other operating income (Details) - EUR (€) € in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021
Other income and expenses
Government grants	€ 553	€ 340
Others	180	26
Total other operating income	€ 733	€ 366	€ 3,209

Other income and expenses - Other operating expenses (Details) - EUR (€) € in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021
Other income and expenses
Currency losses	€ 1	€ 34
Total other operating expenses	€ 1	€ 34	€ 86

Discontinued operations (Details) - EUR (€) € / shares in Units, € in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021
Discontinued operations
Inventories	€ 2,067		€ 3,869
Revenue	10,327	€ 9,981	189,923
Cost of sales	6,450	6,208	160,448
Gross profit	3,877	3,773	29,475
General administrative expenses	7,906	11,596	46,739
Selling expenses	2,394	1,949	9,860
Other operating income	733	366	3,209
Operating income	(10,459)	(13,870)	€ (44,438)
Finance costs, net	620	259
Profit (loss) before tax	(11,079)	(14,129)
Income tax expenses	4
Income for the period	4,601	9,240
Cash flow from discontinued operations
Net cash flow from operating activities	2,835	8,962
Net cash flow from/ (used in) investing activities	575	(1,770)
Net cash flow used in financing activities	(409)	(275)
COVID 19 Segment Discontinued Operations
Discontinued operations
Inventories	0
Revenue	19,463	54,979
Cost of sales	15,200	44,547
Gross profit	4,263	10,432
General administrative expenses	302	999
Selling expenses	7	193
Other operating income	706
Operating income	4,660	9,240
Finance costs, net	46
Profit (loss) before tax	4,614	9,240
Income tax expenses	13
Income for the period	4,601	9,240
Total comprehensive income, attributable to equity holders of the parent	€ 4,601	€ 9,240
Net income per share - Basic and diluted (in EUR)
Basic earnings (loss) per share from discontinued operations (in EUR)	€ 0.20	€ 0.41
Diluted earnings (loss) per share from discontinued operations (in EUR)	€ 0.20	€ 0.41
Cash flow from discontinued operations
Net cash flow from operating activities	€ 2,835	€ 8,962
Net cash flow from/ (used in) investing activities	575	(1,770)
Net cash flow used in financing activities	(409)	€ (275)
COVID 19 Segment Discontinued Operations \| Increase (decrease) due to retrospective correction of classification error
Discontinued operations
Cost of sales	(1,192)
General administrative expenses	999
Selling expenses	€ 193

Trade receivables and other assets (Details) € in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2022 EUR (€)	Mar. 31, 2021 EUR (€)	Mar. 31, 2022 USD ($)	Dec. 31, 2021 EUR (€)
Non-current
Other assets-Rental deposits	€ 2,922			€ 2,922
Other assets-Others	50			50
Trade receivables and contract assets and other assets non-current	2,972			2,972
Current
Trade receivables, net	18,209			21,065
Contract assets, net	2,916			3,272
Other assets	5,443			5,453
Trade receivables and contract assets and other assets current	26,568			29,790
Total non-current and current trade receivables and other assets	29,540			32,762
Expected credit loss allowances on trade receivables and contract assets	146	€ 95
COVID 19 Segment Discontinued Operations
Current
Gross amount of trade receivables and contract assets	8,013			8,263
Trade receivables and contract assets.
Current
Gross amount of trade receivables and contract assets	€ 26,988			€ 30,054
Expected credit loss rate	21.70%		21.70%	19.00%
Expected credit loss	€ 5,863			€ 5,717
Trade receivables and contract assets. \| Not past due
Current
Gross amount of trade receivables and contract assets	€ 9,355			€ 17,978
Expected credit loss rate	1.50%		1.50%	0.90%
Trade receivables and contract assets. \| Less than 1 month
Current
Gross amount of trade receivables and contract assets	€ 2,743			€ 1,476
Expected credit loss rate	6.90%		6.90%	7.70%
Trade receivables and contract assets. \| 1 - 3 months
Current
Gross amount of trade receivables and contract assets	€ 6,487			€ 2,596
Expected credit loss rate	4.80%		4.80%	11.70%
Trade receivables and contract assets. \| Past due more than 90 days
Current
Gross amount of trade receivables and contract assets	€ 8,403			€ 8,004
Expected credit loss rate	62.10%		62.10%	64.10%
Minimum
Current
Receivables payment terms	30 days
Maximum
Current
Receivables payment terms	90 days
Other assets
Current
Consideration receivable for the sale of LPC \| $			$ 50
Current value added tax receivables	€ 346			€ 253
Prepaid expenses	3,128			3,346
Receivables from exercise of share based payments granted	185			116
Receivables from COVID 19 bank or credit card transactions	0			612
Receivables from grants	173			€ 0
Other assets \| Rostock headquarters building
Current
Cash deposits provided as security for bank loans	2,250
Bank guarantee	3,000
Other assets \| Berlin Offices
Current
Cash deposits provided as security for bank loans	193
Bank guarantee	257
Other assets \| Other property, plant and equipment
Non-current
Other assets-Rental deposits	€ 190

Cash and short-term deposits (Details) - EUR (€) € in Thousands	Mar. 31, 2022	Dec. 31, 2021
Secured bank loan
Borrowings
Short term deposits pledged as security	€ 938	€ 938
Overdraft facility
Borrowings
Short term deposits pledged as security	1,000	1,000
Existing Overdraft facility
Borrowings
Short term deposits pledged as security	2,500	€ 2,500
Maximum borrowing capacity	2,500
Second Overdraft facility
Borrowings
Maximum borrowing capacity	500
Third Overdraft facility
Borrowings
Maximum borrowing capacity	€ 500

Equity - Common Shares (Details) € / shares in Units, € in Thousands	1 Months Ended	3 Months Ended	12 Months Ended
	Jan. 31, 2022 EUR (€) shares	Mar. 31, 2022 EUR (€) € / shares shares	Dec. 31, 2021 EUR (€) shares	Jan. 31, 2022 $ / shares	Jan. 31, 2022 € / shares
Disclosure of classes of share capital [line items]
Number of common shares issued (in shares) \| shares	4,479,088
Net offering proceeds, after deducting underwriting discounts, commissions and transaction costs \| €	€ 15,000
Share price \| (per share)				$ 3.73	€ 3.35
Common shares
Disclosure of classes of share capital [line items]
Par value per share (in euros per share) \| € / shares		€ 0.12
Authorized but unissued share capital \| €		€ 6,230	€ 6,772
Number of shares issued and fully paid \| shares		27,081,557	22,567,971

Equity - Capital reserve (Details) € / shares in Units, $ / shares in Units, € in Thousands, $ in Millions	1 Months Ended
	Jan. 31, 2022 EUR (€) € / shares shares	Jan. 31, 2022 USD ($) shares	Mar. 31, 2022 EUR (€) shares	Mar. 31, 2022 $ / shares	Jan. 31, 2022 $ / shares	Dec. 31, 2021 EUR (€)
Net offering proceeds, after deducting underwriting discounts, commissions and transaction costs	€ 15,000
Number of common shares issued (in shares) \| shares	4,479,088	4,479,088
Share price \| (per share)	€ 3.35				$ 3.73
Number of securities called by warrants \| shares	1,343,727		1
Exercise price of warrants \| $ / shares				$ 7.72	7.72
Capital Reserve			€ 143,456			€ 133,897
Warrants Issue Related Cost	€ 2,800
Value of other equity instruments granted under share based payment arrangement	2,800	$ 3.2
Capital reserve
Net offering proceeds, after deducting underwriting discounts, commissions and transaction costs	€ 15,000
Number of common shares issued (in shares) \| shares	4,479,088	4,479,088
Share price \| (per share)	€ 3.35				3.73
Number of securities called by warrants \| shares	1,343,727
Exercise price of warrants \| $ / shares					$ 7.72
Share premium included in capital reserve			118,142			€ 106,665
Value of other equity instruments granted under share based payment arrangement	€ 2,800	$ 3.2
Capital reserve from issuance of shares after transaction costs
Share issue related cost	110
Capital Reserve	€ 14,300
Capital reserve from issuance of shares and warrants after transaction costs
Capital Reserve			€ 11,500

Financial liabilities - Interest-bearing liabilities (Details) - EUR (€) € in Thousands	Mar. 31, 2022	Dec. 31, 2021
Financial liabilities
Total non-current liabilities	€ 36,430	€ 15,394
Total current liabilities	6,527	7,145
Total non-current and current liabilities	42,957	22,539
Total loans
Financial liabilities
Total non-current liabilities	21,890
Total current liabilities	3,574	3,815
Secured bank loans
Financial liabilities
Total non-current liabilities	21,890
Total current liabilities	301	505
Short term deposits pledged as security	938	938
Bank overdrafts
Financial liabilities
Total current liabilities	3,273	3,310
Lease liabilities
Financial liabilities
Total non-current liabilities	14,540	15,394
Total current liabilities	2,953	3,330
Total non-current and current liabilities	€ 17,493	€ 18,724

Financial liabilities - Conditions and statement of liabilities (Details) € in Thousands, $ in Thousands		1 Months Ended		3 Months Ended
	Jan. 31, 2022 EUR (€)	Jan. 31, 2022 EUR (€)	Jan. 31, 2022 USD ($)	Mar. 31, 2022 EUR (€)	Mar. 31, 2021 EUR (€)	Mar. 31, 2022 USD ($)	Jan. 31, 2022 USD ($)	Dec. 31, 2021 EUR (€)
Financial liabilities
Nominal amount				€ 43,415				€ 22,539
Borrowings drawdowns				21,695	€ 1,587
Carrying amount				€ 42,957				€ 22,539
Secured Bank Loans With Maturity Period 2017 To 22
Financial liabilities
Nominal interest rate (as a percent)				2.95%		2.95%		2.95%
Nominal amount				€ 301				€ 505
Carrying amount				€ 301				€ 505
Secured Bank Loans With Maturity Period 2022 To 27
Financial liabilities
Nominal interest rate (as a percent)				7.93%		7.93%
Nominal amount \| $						$ 22,348
Carrying amount \| $						$ 21,890
Bank overdrafts, one
Financial liabilities
Nominal interest rate (as a percent)				4.75%		4.75%		4.75%
Nominal amount				€ 499				€ 499
Carrying amount				€ 499				€ 499
Bank overdrafts, two
Financial liabilities
Nominal interest rate (as a percent)				3.75%		3.75%		3.75%
Nominal amount				€ 2,372				€ 2,329
Carrying amount				€ 2,372				€ 2,329
Bank overdrafts, three
Financial liabilities
Nominal interest rate (as a percent)				4.50%		4.50%		4.50%
Nominal amount				€ 402				€ 482
Carrying amount				402				482
Bank overdrafts, one and three
Financial liabilities
Nominal amount				901				981
Lease liabilities
Financial liabilities
Nominal amount				17,493				18,724
Carrying amount				€ 17,493				€ 18,724
Minimum \| Lease liabilities
Financial liabilities
Nominal interest rate (as a percent)				5.40%		5.40%		5.40%
Nominal interest rate at commencement of leases				2.10%		2.10%		2.10%
Maximum \| Lease liabilities
Financial liabilities
Nominal interest rate (as a percent)				9.10%		9.10%		9.10%
Nominal interest rate at commencement of leases				3.50%		3.50%
Overdraft facility \| Bank overdrafts, two
Financial liabilities
Short-term deposits, pledged as security				€ 2,500				€ 2,500
Second Overdraft facility \| Bank overdrafts, one and three
Financial liabilities
Short-term deposits, pledged as security				€ 500
Loan facility
Financial liabilities
Nominal interest rate (as a percent)	7.93%	7.93%					7.93%
Nominal amount	€ 40,200	€ 40,200					$ 45,000
Transaction costs	€ 648	€ 648
Effective interest rate (as a percent)	10.51%	10.51%					10.51%
Loan facility \| Floor rate
Financial liabilities
Adjustment to interest rate	0.07%	0.07%					0.07%
Loan facility first tranche
Financial liabilities
Borrowings drawdowns	€ 22,300		$ 25,000
Borrowings covenant, Minimum required revenue		€ 30,000
Loan facility second tranche
Financial liabilities
Borrowings available, Subject to achievement of product revenue	€ 17,900	17,900					$ 20,000
Borrowings, Revenue achievement threshold		44,700	$ 50,000
Borrowings covenant, Minimum required revenue		€ 40,000

Financial liabilities - Trade payables and other liabilities (Details) € / shares in Units, $ / shares in Units, $ in Millions	1 Months Ended		3 Months Ended
	Jan. 31, 2022 EUR (€) shares	Jan. 31, 2022 USD ($) $ / shares shares	Mar. 31, 2022 EUR (€) € / shares shares	Mar. 31, 2021 EUR (€)	Mar. 31, 2022 $ / shares	Jan. 31, 2022 € / shares shares	Dec. 31, 2021 EUR (€)
Disclosure of reconciliation of liabilities arising from financing activities
Trade payables			€ 5,897,000				€ 11,252,000
Government grants (deferred income)			9,023,000				9,396,000
Contract liabilities			2,166,000				4,842,000
Warrants liability			2,603,000
Others			12,393,000				14,632,000
Trade payables and other liabilities			32,082,000				40,122,000
Non-current			10,109,000				8,028,000
Current			21,973,000				32,094,000
Grants received for investment in property, plant and equipment			0	€ 0
Provision for outstanding invoices			2,400,000				4,978,000
Personnel related liabilities for vacation and bonuses			4,031,000				4,812,000
VAT payable			0				905,000
Liabilities for wage and church tax			€ 755,000				€ 1,040,000
Amount of warrant liabilities per share \| € / shares			€ 1.93			€ 2.11
Decrease in fair value of warrant liabilities			€ 238,000
Net offering proceeds, after deducting underwriting discounts, commissions and transaction costs	€ 15,000,000.0
Shares issued during period \| shares	4,479,088	4,479,088
Share price \| (per share)		$ 3.73				€ 3.35
Number of securities called by warrants \| shares		1,343,727	1			1,343,727
Exercise price of warrants \| $ / shares		$ 7.72			$ 7.72
Value of other equity instruments granted under share based payment arrangement	€ 2,800,000	$ 3.2

Financial liabilities - Key assumptions to derive warrants value (Details)	Mar. 31, 2022 $ / shares Y	Jan. 31, 2022 $ / shares Y
Exercise price
Disclosure of sensitivity analysis of fair value measurement to changes in unobservable inputs, liabilities [line items]
Assumptions used to derive warrants value	7.72	7.72
Share price at grant date
Disclosure of sensitivity analysis of fair value measurement to changes in unobservable inputs, liabilities [line items]
Assumptions used to derive warrants value	4.21	4.42
Volatility
Disclosure of sensitivity analysis of fair value measurement to changes in unobservable inputs, liabilities [line items]
Assumptions used to derive warrants value	0.80	0.80
Risk-free interest rate
Disclosure of sensitivity analysis of fair value measurement to changes in unobservable inputs, liabilities [line items]
Assumptions used to derive warrants value	0.0163	0.0165
Dividend yield
Disclosure of sensitivity analysis of fair value measurement to changes in unobservable inputs, liabilities [line items]
Assumptions used to derive warrants value	0	0
Time to maturity
Disclosure of sensitivity analysis of fair value measurement to changes in unobservable inputs, liabilities [line items]
Assumptions used to derive warrants value \| Y	4.75	4.9

Share-based payments - Expenses from share-based payment arrangements (Details) - EUR (€) € in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Expenses arising from share-based payment transactions
Expenses arising from equity-settled share-based payment transactions	€ (1,957)	€ 2,042
Management board and employees
Expenses arising from share-based payment transactions
Expenses arising from equity-settled share-based payment transactions	470	429
New CEO
Expenses arising from share-based payment transactions
Expenses arising from equity-settled share-based payment transactions	113	799
Supervisory board members
Expenses arising from share-based payment transactions
Expenses arising from equity-settled share-based payment transactions	415	€ 814
Forfeiture Of Management Board Grants
Expenses arising from share-based payment transactions
Expenses arising from equity-settled share-based payment transactions	(179)
Expected forfeiture of management board grants
Expenses arising from share-based payment transactions
Expenses arising from equity-settled share-based payment transactions	€ (2,775)

Share-based payments - Equity share option - Replacement (ESOP VSOP 2017) (Details) - 3 months ended Mar. 31, 2022	EquityInstruments Options $ / shares shares	EquityInstruments Options € / shares shares
Equity share option 2017 (Equity settled) \| Options.
Number
Outstanding at January 1 \| Options	357,440	357,440
Outstanding as of March 31 \| Options	357,440	357,440
Vested as of March 31 \| shares	357,440	357,440
Exercisable as of March 31 \| Options	357,440	357,440
WAEP
Outstanding as of January 1 \| € / shares		€ 0.12
Granted during the year \| € / shares		0.12
Exercised during the year \| € / shares		0.12
Forfeited during the year \| € / shares		0.12
Expected forfeited during the year \| € / shares		0.12
Outstanding as of March 31 \| € / shares		€ 0.12
2019 Plan \| Options.
Number
Outstanding at January 1 \| Options	185,077	185,077
Outstanding as of March 31 \| Options	185,077	185,077
Vested as of March 31 \| shares	115,758	115,758
Exercisable as of March 31 \| Options	115,758	115,758
WAEP
Outstanding as of January 1 \| $ / shares	$ 11.76
Outstanding as of March 31 \| $ / shares	$ 11.76
2019 Plan \| RSUs
Number
Outstanding as of January 1 \| EquityInstruments	1,803,968	1,803,968
Granted during the year \| EquityInstruments	647,056	647,056
Exercised during the year \| EquityInstruments	(34,498)	(34,498)
Forfeited during the year (in shares) \| EquityInstruments	(60,340)	(60,340)
Expected forfeited during the year \| shares	(754,572)	(754,572)
Outstanding as of March 31 \| EquityInstruments	1,601,614	1,601,614
Vested as of March 31 \| shares	448,144	448,144
Exercisable as of March 31 \| EquityInstruments	448,144	448,144

Share-based payments - Management board and employees Options and RSUs grants awarded and exercises (Details) - 2019 Plan	3 Months Ended
	Mar. 31, 2022 EquityInstruments tranche
RSUs
Disclosure of terms and conditions of share-based payment arrangement [line items]
RSUs granted	647,056
RSU Granted One
Disclosure of terms and conditions of share-based payment arrangement [line items]
RSUs granted	166,667
Number of tranches \| tranche	4
Vesting period	4 years
Expiration Date	10 years
RSU Granted Two
Disclosure of terms and conditions of share-based payment arrangement [line items]
RSUs granted	174,394
Number of tranches \| tranche	4
Vesting period	4 years
Expiration Date	10 years
RSU Granted Four
Disclosure of terms and conditions of share-based payment arrangement [line items]
Expiration Date	10 years
RSU Granted Four \| Maximum
Disclosure of terms and conditions of share-based payment arrangement [line items]
RSUs granted	275,000
RSU Granted Five
Disclosure of terms and conditions of share-based payment arrangement [line items]
RSUs granted	30,995
Number of tranches \| tranche	4
Vesting period	4 years
Expiration Date	10 years

Share-based payments - Valuation of Options (Details) - Performance Based RSUs - New CEO	3 Months Ended
	Mar. 31, 2022 item $ / shares
Tranche one
Key assumptions used to derive other equity instruments value
Share price at grant date (USD)	$ 4.42
Fair value	$ 2.10
Vesting hurdle \| item	12
Expected volatility (%)	80.00%
Riskfree rate (%)	1.10%
Time to vesting hurdle year	1 year 10 months 28 days
Dividend yield (%)
Tranche two
Key assumptions used to derive other equity instruments value
Share price at grant date (USD)	$ 4.42
Fair value	$ 1.60
Vesting hurdle \| item	15
Expected volatility (%)	80.00%
Riskfree rate (%)	1.10%
Time to vesting hurdle year	1 year 10 months 28 days
Dividend yield (%)

Share-based payments - Grants to new CEO and supervisory board grant (Details) $ / shares in Units, € in Thousands, $ in Millions				1 Months Ended		3 Months Ended
	Apr. 30, 2022 EquityInstruments shares	Feb. 01, 2022 CHF (SFr) EquityInstruments	Feb. 01, 2022 EUR (€) installment $ / shares	Jan. 31, 2022 EUR (€)	Jan. 31, 2022 USD ($)	Mar. 31, 2022 EUR (€) EquityInstruments	Mar. 31, 2022 $ / shares	Mar. 31, 2021 tranche
Share-based Compensation
Value of other equity instruments granted under share based payment arrangement				€ 2,800	$ 3.2
RSUs
Share-based Compensation
Amount of dividend payment expected over an vesting period \| €						€ 0
RSUs \| Mr. Just
Share-based Compensation
Number of units vested during the period						0
Value of other equity instruments derecognized in Share-based payment arrangement \| €						€ 179
Chief Executive Officer \| Subject to time-vesting
Share-based Compensation
Vesting period						4 years
Chief Executive Officer \| RSUs
Share-based Compensation
Contractual life		10 years
Number of Installments \| installment			4
Chief Executive Officer \| RSUs \| Subject to time-vesting and performance vesting
Share-based Compensation
RSUs granted		174,394
Chief Executive Officer \| RSUs \| Subject to time-vesting
Share-based Compensation
RSUs granted		166,667
Chief Executive Officer \| RSUs \| Annual RSUs
Share-based Compensation
RSUs granted		44,444
Vesting term		4 years
Number of Installments \| installment			4
Chief Executive Officer \| Performance Based RSUs \| Tranche one
Share-based Compensation
Vesting percentage		50.00%
Chief Executive Officer \| Performance Based RSUs \| Tranche two
Share-based Compensation
Vesting percentage		50.00%
Chief Executive Officer \| Other RSUs granted to CEO \| Annual RSUs
Share-based Compensation
Value of other equity instruments granted under share based payment arrangement \| SFr		SFr 200,000
Chief Executive Officer \| M&A RSUs
Share-based Compensation
Fair value of units granted during the period \| €			€ 156
Chief Executive Officer \| If change in control of the Company \| M&A RSUs
Share-based Compensation
Number of units vested during the period		275,000
Chief Executive Officer \| VWAP prior to change, between USD 5 and USD 15 \| M&A RSUs
Share-based Compensation
RSUs granted		200,000
Chief Executive Officer \| VWAP prior to change, between USD 5 and USD 15 \| M&A RSUs \| Minimum
Share-based Compensation
Share hurdle price \| $ / shares			€ 5
Chief Executive Officer \| VWAP prior to change, between USD 5 and USD 15 \| M&A RSUs \| Maximum
Share-based Compensation
Share hurdle price \| $ / shares			15
Chief Executive Officer \| VWAP prior to change More Than USD 15 \| M&A RSUs
Share-based Compensation
RSUs granted		275,000
Chief Executive Officer \| VWAP prior to change More Than USD 15 \| M&A RSUs \| Minimum
Share-based Compensation
Share hurdle price \| $ / shares			€ 15
Former Chief Executive Officer \| RSUs
Share-based Compensation
Number of Awards	62,284
Number of units vested during the period	69,428
Number of units cancelled during the period \| shares	7,144
Value of other equity instruments derecognized in Share-based payment arrangement \| €						€ 2,775
Former Chief Executive Officer \| RSUs \| Maximum
Share-based Compensation
RSUs granted	62,284
Number of Awards	62,284
2019 Plan \| RSUs
Share-based Compensation
RSUs granted						647,056
Number of units vested during the period						34,498
2019 Plan \| Management board and employees \| RSUs
Share-based Compensation
RSUs granted		30,995
Number of units vested during the period						34,498
Weighted average fair value of RSUs granted \| $ / shares							$ 3.23
Weighted average exercise price of other equity instruments exercised or vested in share-based payment arrangement \| $ / shares							$ 4.78
2019 Plan \| Management board and employees \| Vesting in four tranches \| RSUs
Share-based Compensation
Contractual life		10 years
Vesting term								4 years
Number of Tranches \| tranche								4

Financial instruments at fair value - Recurring basis (Details) - EUR (€) € in Thousands	3 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Disclosure of fair value measurement of liabilities [line items]
Warrant liability fair value	€ 238
Financial liabilities at amortized cost
Disclosure of fair value measurement of liabilities [line items]
Fair value of non-current loans	21,890
Recurring
Disclosure of fair value measurement of liabilities [line items]
Fair value of non-current loans	21,890	€ 0
Warrants liability	2,603
Recurring \| Level 2
Disclosure of fair value measurement of liabilities [line items]
Fair value of non-current loans	21,890
Recurring \| Level 3
Disclosure of fair value measurement of liabilities [line items]
Warrants liability	€ 2,603

Financial instruments at fair value - Profit or loss impact on the fair values of Level 3 (Details) € in Thousands	3 Months Ended
	Mar. 31, 2022 EUR (€)
Financial instruments at fair value
Expected volatility increase	€ 3,031
Expected volatility decrease	€ 2,641
Percentage of reasonably possible increase	5.00%

Financial risk management - Currency risk (Details) - Currency risk - EUR (€) € in Thousands	Mar. 31, 2022	Dec. 31, 2021
USD
Currency risk
Net exposure	€ (20,418)	€ 2,241
USD \| Trade receivables and other assets
Currency risk
Net exposure	3,849	4,635
USD \| Trade payables and other liabilities
Currency risk
Net exposure	(2,377)	(2,394)
USD \| Financial liabilities
Currency risk
Net exposure	(21,890)
INR
Currency risk
Net exposure	13	4
INR \| Trade receivables and other assets
Currency risk
Net exposure	€ 13	8
INR \| Trade payables and other liabilities
Currency risk
Net exposure		€ (4)

Financial risk management - Sensitivity analysis (Details) - EUR (€) € in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Financial instruments at fair value
Earnings before tax, 5% increase	€ 953	€ (101)
Earnings before tax, 5% decrease	(1,053)	112
Equity, 5% increase	953	(101)
Equity, 5% decrease	€ (1,053)	€ 112

Financial risk management - Interest rate risk (Details) - EUR (€) € in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Interest rate risk
Disclosure of nature and extent of risks arising from financial instruments [line items]
Decrease in earnings due to 1% increase in interest rate	€ 41	€ 0

Commitments (Details) - EUR (€) € in Thousands	3 Months Ended	12 Months Ended
Commitments (Details) - EUR (€) € in Thousands	Mar. 31, 2022	Dec. 31, 2021
Lease commitments
Total payment obligation	€ 3,126	€ 6,620
Rostock headquarters building \| Not later than one year
Lease commitments
Future lease payments to be made	113	107
Rostock headquarters building \| 1 - 5 years
Lease commitments
Future lease payments to be made	2,373	2,370
Rostock headquarters building \| More than five years
Lease commitments
Future lease payments to be made	4,056	4,219
Office equipment and storage spaces \| Not later than one year
Lease commitments
Future lease payments to be made	39	44
Office equipment and storage spaces \| 1 - 5 years
Lease commitments
Future lease payments to be made	€ 40	€ 49

Contingent Liabilities (Details) - EUR (€)	Aug. 07, 2021	Dec. 31, 2020	Nov. 08, 2018
Universitair Medisch Centrum Utrecht
Contingent Liabilities
Amount in dispute		€ 1,300,000	€ 880,000
Prof. Dr. Peter Bauer
Contingent Liabilities
Aggregate amount in question	€ 42,268.50

Subsequent Events (Details) - Leadership transition € in Thousands	Jun. 29, 2022 EquityInstruments shares	Jun. 22, 2022 EUR (€) EquityInstruments installment
RSUs \| Volkmar Weckesser
Subsequent Event
Number of units vested during the period	10,000
Number of stock cancelled automatically	20,000
Options \| Volkmar Weckesser
Subsequent Event
No of options vested during the period \| shares	33,773
Terms of award	12 months
Forfeit during the year (in shares)	10,000
Number of stock cancelled automatically	15,000
Performance Based RSUs \| CFO
Subsequent Event
RSUs granted		58,132
Number of Installments \| installment		2
Time Based RSUs \| CFO
Subsequent Event
RSUs granted		55,556
Number of Installments \| installment		4
Long-term Incentives (LTIs)
Subsequent Event
Percentage of award constitutes RSU's		75.00%
Percentage of award constitutes stock options		25.00%
Number of Installments \| installment		4
Contractual life		10 years
Long-term Incentives (LTIs) \| Supervisory board members
Subsequent Event
Value of options and other equity instruments granted \| €		€ 140
Long-term Incentives (LTIs) \| Chairman
Subsequent Event
Value of additional options and other equity instruments granted \| €		105
Long-term Incentives (LTIs) \| Vice chairman
Subsequent Event
Value of additional options and other equity instruments granted \| €		70
Long-term Incentives (LTIs) \| Chairman of audit committee
Subsequent Event
Value of additional options and other equity instruments granted \| €		70
Long-term Incentives (LTIs) \| Chairman of compensation committee
Subsequent Event
Value of additional options and other equity instruments granted \| €		€ 14